Clinical Trial Pr otocol : HGT -HIT-094
Study Title: A Controlled, Randomized , Two - a rm, Open -label, Assessor - blinded, 
Multicenter Study  of Intrathecal Idursulfase -IT Administered in 
Conjunction with Elaprase®in Pediatric Patients with Hunter 
Syndrome and Ea rly Cognitive I mpairment
Study Number: HGT -HIT
-094
Study Phase: Phase II/III
Investigational 
Product and 
Device :idursulfase for i ntrathecal use(idursulfase -IT[HGT -2310]), 
SOPH -A-PORT®Mini S, I mplantable Access Port, Spinal, Mini 
Unattached, with Gu idewire (SOPH -A-PORT Mini S)
IND Number: 100,610
Indication: Long-term treatment of Hunter s yndrome in patients with cognitive 
impairment to slow progression of cognitive and functional 
impairment
Study Center(s): Multicenter
Principal 
InvestigatorJoseph Muenzer, MD, PhD
Sponsor: Shire Human Genetic Therapies, Inc.
Sponsor Contact :300 Shire Way
Lexington, MA  02421 USA
Medical Monitor: , MD, PhD
Date
Original Protocol : 04April 2013
Confidentiality Statement
This document is the proprietary  and confidential propert y of 
Shire Human Genetic Therapies, Inc.  Page 1
PPD
PPD
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 2TABLE OF  CONTENTS
SYNOPSI S.................................................................................................................................8
LIST OF ABBREVIATIONS AND DE FINIT IONS OF TERMS ..........................................18
1 INTRODUCTION ...........................................................................................................22
1.1 Mucopoly saccharidosis II (Hunter s yndrome) .......................................................22
1.2 Unmet Medical Need .............................................................................................22
1.3 Overview of Results of Phase I/II Studies .............................................................23
1.3.1
Rationale for Current Phase II/III Study ......................................................24
2 STUDY OBJECTIVES ....................................................................................................26
2.1 Primary  Objective ..................................................................................................26
2.2 Secondary  Objectives .............................................................................................26
2.3 Safety  Objectives ...................................................................................................26
2.4 SOPH -
A-PORT Mini S Device Objectives: ..........................................................26
2.5 Pharmacokinetic and Pharmacod ynamic Objectives .............................................27
2.6 Health Status Objective ..........................................................................................27
2.7 Substudy  Objective ................................................................................................27
3 STUDY ENDPOINTS .....................................................................................................28
3.1 Primary  Efficacy  Endpoint ....................................................................................28
3.2 Secondary  Efficacy  Endpoints ...............................................................................28
3.3 Pharmacokinetic and Pharmacod ynamic Endpoints ..............................................28
3.4 Safety Assessments ................................................................................................29
3.5 SOPH -
A-PORT Mini S Device Assessments........................................................29
3.6 Health Status Assessment ......................................................................................29
4 INVESTIGAT
IONAL PLAN ..........................................................................................30
4.1 Overall Study  Design and Plan ..............................................................................30
4.1.1
Intrathecal Drug Delivery ................................ ................................ ............ 30
4.2 Rationale for Study  Design and Comparator Group ................................ .............. 31
4.2.1 Rationale for Dose Selection .......................................................................33
4.3 Study  Duration ................................ ................................ ................................ .......34
5 STUDY POPUL ATION SEL ECTION ................................ ................................ ........... 35
5.1 Study  Population ................................ ................................ ................................ ....35
5.2 Inclusion Criteria ................................ ................................ ................................ ...35
5.2.1 Inclusion Criteria for the Pivotal Study .......................................................35
5.3 Exclusion Criteria
..................................................................................................37
6 STUDY TREATMENT ................................ ................................ ................................ ...39
6.1 Description of Treatments......................................................................................39Page 2
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 36.1.1 Investigational Product ................................ ................................ ................ 39
6.1.2 Intrathecal Drug Delivery  Device ................................................................39
6.1.3 Comparator ..................................................................................................39
6.2 Treatments Administered .......................................................................................40
6.3 Selection and Timing of Dose for Each Patient .....................................................40
6.4
Method of Assigning Patients to Treatment Groups..............................................40
6.5
Blinding..................................................................................................................41
6.6 Infusion Reactions and Management .....................................................................41
6.7 Restrictions ............................................................................................................42
6.7.1 Prior Therap y
...............................................................................................42
6.7.2 Fluid and Food Intake ..................................................................................42
6.7.3 Patient Activity  Restrictions ........................................................................42
6.8 Treatment Compliance ...........................................................................................42
6.9
Packaging and Labeling .........................................................................................43
6.9.1 Investigational Product ................................................................................43
6.9.2
Intrathecal Drug Delivery  Device ................................................................43
6.9.3 Storage and Accountability ..........................................................................43
6.9.4 Investigational Product ................................................................................43
6.9.5 Intrathecal Drug Delivery  Device ................................................................44
6.9.6 Comparator Product .....................................................................................44
7
STUDY PROCEDURES .................................................................................................45
7.1 Informed Consent ...................................................................................................46
7.2 Study  Entrance Criteria ..........................................................................................46
7.3 Medical History .....................................................................................................47
7.4 Echocardiogram .....................................................................................................47
7.5
Device Related Procedures ....................................................................................47
7.5.1 IDDD Implantation and Revision ................................................................47
7.5.2
X-ray Verification of Intrathecal Drug Delivery  Device Placement ...........48
7.5.3 CSF Sampling Procedure ................................ ................................ ............. 48
7.5.4 Device Removal ................................ ................................ ........................... 48
7.6 Investigational Product Administration ................................ ................................ .48
7.7 Pharmacokinetic Assessment s ................................ ................................ ............... 49
7.8 Pharmacod ynamic Assessments ............................................................................49
7.9 Efficacy  Assessments ................................ ................................ ............................. 50
7.9.1 Neurodevelopmental Assessment Tools ................................ ...................... 50
7.10 Health Status Assessment ................................ ................................ ...................... 50
7.11 Safety  Assessments ................................ ................................ ................................ 50
7.11.1 Physical and Neurological Examination ......................................................51Page 3
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 47.11.2 Height and Weight ................................ ................................ ....................... 51
7.11.3 Head Circumference ....................................................................................51
7.11.4 Hearing Assessment .....................................................................................51
7.11.5 Vital Signs ....................................................................................................51
7.11.6 Electrocardiogram ........................................................................................52
7.11.7 Intracranial Pressure Measurement ..............................................................52
7.11.8
Brain Magnetic Resonance Imaging............................................................52
7.11.9 Clinical and Other Laboratory  Tests ............................................................52
7.11.10 Cerebrospinal Fluid Assessments ................................................................53
7.11.11 Antibody  Assessments .................................................................................53
7.11.12 Device Assessments .....................................................................................54
7.11.13 Pregnancy  Testing ........................................................................................54
7.12 Sample Collection, Storage, and Shipping ............................................................54
7.13 Concomitant Medications, Therapies/Interventions, and Medical/S
urgical 
Procedures Assessme nts........................................................................................54
7.14 Adverse Events Assessments .................................................................................54
7.14.1 Definitions of Adverse Events and Serious Adverse Events .......................54
7.14.1.1 Adverse Events ..................................................................................54
7.14.1.2 Elaprase Infusion -related Adverse Events .........................................55
7.14.1.3 IDDD -related Adverse Events ................................ ........................... 55
7.14.1.4 Device Surgical Procedure -related Adverse Events ..........................56
7.14.1.5 Intrathecal Administr ation Process Adverse Events
..........................56
7.14.1.6 Serious Adverse Event .......................................................................56
7.14.1.7 Unexpected Adverse Device Event ....................................................56
7.14.2 Device -associated Definitions .....................................................................57
7.14.2.1 Device Revision (Partial and Full) .....................................................57
7.14.2.2 Device Malfunction ...........................................................................57
7.14.2.3 Device Failure ....................................................................................57
7.14.3 Classification of Adverse Events and Serious Adverse Event s
...................57
7.14.3.1 Clarification between Serious and Severe .........................................57
7.14.4 Relatedness of Adverse Events and Serious Adverse Events ...................... 58
7.14.5 Procedures for Recording and Reporting Adverse Events .......................... 59
7.14.5.1 Adverse Event Monitoring and Period of Observation......................59
7.14.5.2 Reporting Serious Adverse Events ................................ .................... 59
7.15 Pregnancy ................................ ................................ ................................ ............... 60
7.16 Abuse, Overdose, and Medication Error................................ ................................ 60
7.17 Removal of Patients from the Trial or Investigational Product ............................. 61
7.18 Other Study  Procedures ................................ ................................ ......................... 61Page 4
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 57.18.1 Safety -related Study  Stopping Rules ...........................................................61
7.19 Appropriateness of Measurements .........................................................................62
8 STUDY ACTIVIT IES.....................................................................................................64
8.1 Screening (Month -1, Week -4 to -
1).....................................................................64
8.1.1 All Patients in the P ivotal Study  and Substudy ...........................................64
8.2 Randomization/Enrollment: Clinic Admission (Month 0, Week 0, Day  0)
..........65
8.2.1 All Patients (I T Treatment and No IT Treatment Groups) in the Pivotal 
Study ............................................................................................................65
8.2.2 All Patients in the Substudy .........................................................................65
8.3
Treatment Period (Months 1 to 12) ........................................................................65
8.3.1 Patients in the I
T Treatment Group of the Pivotal Study  and All Patients in 
the Substudy : Surgery  and Post -op Recovery  (Weeks 2 and 3) ..................65
8.3.1.1 Pre-surgery .........................................................................................65
8.3.1.2 Surgery ...............................................................................................65
8.3.1.3 Follow up ...........................................................................................66
8.3.2 Patients in the I
T Treatment Group of the Pivotal Study  and All Patients in 
the Substudy : IT Dosing (Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 
[± 7 day s])....................................................................................................66
8.3.2.1 Pre-treatment ......................................................................................66
8.3.2.2 IT Injection .........................................................................................66
8.3.2.3 Follow Up ..........................................................................................67
8.3.3 Patients in the No I T Treatment Group of the Pivotal Study  (Months 1 to 
12)
................................................................................................................67
8.3.3.1 Weeks 4, 16, 28, 40 (± 7 day s)...........................................................67
8.3.3.2 Weeks 8, 12, 20, 24, 32, 36, 44, 48 (± 7 day s)...................................67
8.4 End of Study : Month 13 (Week 52[± 7 day s])......................................................68
8.4.1
Patients in the I T Treatment Group of the Pivotal Study  and All Patients in 
the Substudy .................................................................................................68
8.4.2 Patients in the No I T Treatment Group of the Pivotal Study .......................68
8.5 Follow -up Visit (Day  7 [±2 Day s] Post EOS) ................................ ....................... 69
8.5.1 All Patients in the Pivotal Study  and Substudy ................................ ........... 69
9 QUALITY CONTROL AND ASSURANCE .................................................................70
10 STATI STICAL ANALYSI S
...........................................................................................71
10.1 General Methodology ................................ ................................ ............................ 71
10.2 Determination of Sample Size ................................ ................................ ............... 71
10.3 Method of Assigning Study  Patients to Treatment Groups ................................ ...72
10.4 Population Description and Exposure ................................ ................................ ....72
10.4.1 Analy sis Populations ................................ ................................ .................... 72
10.4.2 Patient Disposition ................................ ................................ ....................... 72Page 5
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 610.4.3 Protocol Deviations ................................ ................................ ...................... 73
10.4.4 Demographics and Baseline Characteristics................................................73
10.4.5 Treatment Compliance .................................................................................73
10.4.6 Extent of Exposure .......................................................................................73
10.5 Analy sis of Efficacy ...............................................................................................73
10.5.1 Primary  Efficacy  Endpoint Analy sis...........................................................74
10.5.2 Key Secondary  Efficacy  Endpoint Analy sis................................................74
10.5.3 Other Secondary  Efficacy  Endpoints Anal yses................................ ........... 75
10.5.4 Exploratory  Subset Analy ses.......................................................................75
10.6 Pharmacokinetic, Pharmacod ynamic and Health Status Outcomes ......................76
10.6.1 Pharmacokinetic Measurements and Parameters .........................................76
10.6.2 Pharmacod ynamic Outcome ........................................................................76
10.6.3 Health Status Outcome ................................................................................76
10.7 Safety  Assessments ................................................................................................76
10.7.1 Adverse Eve nts............................................................................................77
10.7.1.1 Adverse Events ..................................................................................77
10.7.1.2 IDDD and Procedure Related Adverse Events
..................................77
10.7.2 Clinical L aboratory  Evaluations ..................................................................77
10.7.3 ECG Evaluations ..........................................................................................77
10.7.4 Vital Signs and Phy sical Meas
urements ......................................................77
10.7.5 Physical Findings .........................................................................................78
10.7.6 Other Observations Related to Safet y
..........................................................78
10.7.6.1 Hearing Assessments .........................................................................78
10.7.6.2 Immunogenicit y
.................................................................................78
10.7.6.3 Device Performance ...........................................................................78
10.7.7
Concomitant Medications ............................................................................79
10.8 Statistical/Analy tical Issues ...................................................................................79
10.8.1 Handling of Drop -outs and Missing Data ....................................................79
10.8.2
Adjustment for Covariates ................................ ................................ ........... 79
10.8.3 Interim Anal ysis................................ ................................ ........................... 79
10.8.4 Multicenter Studies ................................ ................................ ...................... 79
10.8.5 Multiple Comparisons/Multiplicity ................................ ............................. 80
10.8.6 Sensit ivity Anal yses.....................................................................................80
11 ADMINISTRATIVE CONSI DERATIONS
................................ ................................ ....81
11.1 Investigators and Study  Administrative Structure ................................ ................. 81
11.2 Institutional Review Board or Independent Ethics Committee Approval ............. 81
11.3 Ethical Conduct of the Study ................................ ................................ ................. 81
11.4 Patient I nformation and Consent ................................ ................................ ........... 82Page 6
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 711.5 Patient Confidentiality ................................ ................................ ........................... 82
11.6 Study  Monitoring ...................................................................................................83
11.7 Case Report Forms and Study  Records .................................................................83
11.7.1 Critical Documents ......................................................................................83
11.8 Data Safet y Monitoring Board ...............................................................................84
11.9
Device Failure Adjudication Process.....................................................................84
11.10 Protocol Violations/Deviations ..............................................................................84
11.11 Premature Closure of the Study .............................................................................85
11.12
Access to Source Documentation ..........................................................................85
11.13 Data Generation and Analy sis...............................................................................86
11.14 Retention of Data ...................................................................................................86
11.15 Financial Disclosure ...............................................................................................86
11.16 Publication and Disclosure Policy .........................................................................86
12 LIST OF REFERENCES .................................................................................................88
13 APPENDI CES .................................................................................................................90
LIST OF IN-
TEXT TABLES
Table 7-1  Assessments for Phy sical Examinations ......................................................51
Table 7
-2 List of Laboratory  Tests ...............................................................................52
Table 7
-3 Adverse Event Severit y................................................................................57
Table 7
-4 Adverse Event Relatedness ..........................................................................58
Table 7-5. Endpoint Model ................................ ................................ ................................ 63
LIST OF APPENDICES
Appendix 1 Schedule of Events for Patients Randomized to Treatment in the 
Pivotal Study ................................ ................................ ................................ 90
Appendix 2 Schedule of Events for Patients Randomized to No Treatment in the 
Pivotal Study ................................................................................................93
Appendix 3 Schedule of Events for Patients Enrolled in the Substudy ...........................95
Appendix 4 Expected Adverse Device Effects ................................................................98
Appendix 5 Protocol Signature Page
................................ ................................ ............. 100Page 7
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 8SYNOPSIS
Sponsor:
Shire Human Genetic Therapies, Inc.
Names of Investigational Product and Device:
idursulfase for intrathecal use (idur sulfase -IT [HGT -2310])
SOPH -A-PORT®Mini S, I mplantable Access Port, Spinal, Mini Unattached, with 
Guidewire (SOPH -A-PORT Mini S)
Study Title:
A Controlled, Randomized, Two-arm, Open -label, Assessor -blinded, Multicenter Study  of 
Intrathecal Idursulfase -ITAdministered in Conjunction with Elaprase®in Pediatric 
Patients with Hunter Sy ndrome and Early  Cognitive I mpairment
Study Number:
HGT -HIT
-094
Study Phase: 
Phase II/III
Investigational Product Dose, Mode of Administration: 
idursulfase -IT 10 mg, intra thecal (IT) injection
Device, Intended Use:
The SOPH -A-PORT®Mini S is a sy stem intended for implantation by  physicians.  The 
SOPH -A-PORT Mini S, once implanted, allows healthcare personnel to administer 
idursulfase -IT (HGT -2310) indicated for ITdelivery intermittently  over a long period of 
time. 
Comparator, Dose, and Mode of Administration:
No treatment
Treatment Regimen:
Once monthly  (ie, every  28 day s) ITadministration of idursulfase -IT 10 mg for 12 months 
via a surgically implanted intrathecal dru g delivery  device ( IDDD ), or lumbar puncture 
Primary Objective: 
To determine the effect of the treatment regimen in pediatric patients with Hunter 
syndrome and early cognitive impairment on the General Conceptual Ability 
(GCA) score as measured by  the D AS-II,in conjunction with Elaprase therapy
Key Secondary Objective:
To determine the effect of the treatment regimen in pediatric patients with Hunter 
syndrome and earl y cognitive impairment on the Adaptive Behavior Composite 
(ABC) score as measured by  the VABS -II,in conjunction with Elaprase therapy
Secondary Objectives:
To determine the effect of the treatment regimen in pediatric patients with Hunter 
syndrome and earl y cognitive impairment, in conjunction with Elaprase therap y, on:
Cognitive function a s measured b y the cluster areas and subtests of the DAS -IIPage 8
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 9Adaptive behavior as measured b y the domains of the VABS -II
Safety Objectives:
To determine the effect of the treatment regimen on safet y as assessed b y adverse 
events, clinical laboratory  testin g, ph ysical examination findings, vital signs, and 
electrocardiogram (ECG) recordings
To evaluate the anti- idursulfase antibody  response in serum and CSF during the 
treatment regimen
SOPH -A-PORT Mini S Device Objectives:
To determine the safet y and perfor mance of the SOPH -A-PORT Mini S device
Pharmacokinetic and Pharmacodynamic Objectives:
To evaluate the concentration of idursulfase in serum and cerebrospinal fluid 
(CSF) after IT administration and determine pharmacokinetic parameters
To determine the ef fect of the treatment regimen on the concentration of 
glycosaminogl ycan (GAG) in CSF
Health Status Objective:
To evaluate health status as measured b y the EQ -5D instrument
Substudy Objective:
To examine the effect of the treatment regimen in pediatric p atients with Hunter 
syndrome <3 y ears old and having a complex rearrangement genot ype of the 
iduronate -2-sulfatase gene on safet y and efficacy  measures
Study Efficacy Endpoints: 
The primary  efficacy  endpoint of this study  is:
Change from baseline in the GCA score after 12 months of treatment, at Visit 
Week 52, as obtained b y DAS -II testing
The key  secondary  efficacy  endpoint of this study  is:
Change from baseline in the ABC score after 12 months of treatment at Visit 
Week 52, as obtained b y VABS -II testin g
The secondary  efficacy  endpoints of this study  are:
Change from baseline to Visit Weeks 16, 28, and 40 in the GCA score as obtained 
by DAS -II testing
Change from baseline to Visit Weeks 16, 28, and 40 in the ABC score as obtained 
by VABS -II testing
Chang e from baseline to Visit Weeks 16, 28, 40 ,and 52  in standardized scores in 
cluster areas of the DAS -
II: Verbal, Nonverbal, Spatial, and Special Nonverbal 
Composite (SNC)
Change from baseline to Visit Weeks 16, 28, 40, and 52 in the standardized 
domain sc ores of the VABS -II: Communication, Daily Living Skills, 
Socialization, Motor Skills, and Maladaptive Behavior
Change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents and 
development quotient (DQ) for the subcategories of the DAS- II (Verbal 
Comprehension, Picture Similarities, Naming Vocabulary , Pattern Construction, 
Matrices and Cop ying for the DAS -II/Earl y Years, and Recall of Designs, Word Page 9
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 10Definitions, Pattern Construction, Matrices, Verbal Similarities ,and Sequential 
and Quantitat ive Reasoning for the DAS -II/School Years)
Change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents and 
developmental quotients of the VABS -II: Communication, Daily Living Skills, 
Socialization, Motor Skills, and Maladaptive Behavior
Study Population: 
42 male patients (14 untreated, 28 treated) are planned.
Study Design:
This is a 
controlled, randomized, 2-arm, open -label, assessor - blinded , multicenter study  to 
determine the effect on clinical parameters of neurodevelopmental status of monthly  IT 
administration of idursulfase -IT 10 mg for 12 months in pediatric patients with Hunter 
syndrome and cognitive impairment who have previously  received and tolerated a 
minimum of 3 months of therap y with Elaprase.  
All patients will continue t o receive Elaprase therapy as standard of care throughout the 
study .  Elaprase will not be provided b y the Sponsor , but rather will be prescribed b y the 
patient’s phy sician in accordance with local prescribing information. 
The pivotal study  design is “no IT treatment -controlled” in that 
28 patients are assigned 
randomly  to receive IT treatment and 14 patients are assigned randomly  to participate 
without receiving IT treatment
.  
The pivotal study  will consist of a Screening period of up to 28 day s prior to
randomization.  Those patients randomized to ITtreatment will undergo surgical 
implantation of the SOPH-A- PORT Mini S IDDD followed by  a post -operative recovery  
period of at least 14 day s prior to the first ITadministration of idursulfase -IT.  Treated 
patients will then receive 12 monthly  IT injections of 10 mg idursulfase -IT corresponding 
to a treatment and assessment interval of 13 (28 -day) months from randomization to the 
end-
of-study  (EOS) evaluations.  L ikewise, patients randomized to no IT treatment will be 
assessed over 13 (28-day) months 
after randomization.
Patients in the IT treatment arm of the pivotal study will be assessed according to the 
following schedule: 
Screening (Weeks -1 to -4 [Day  -28 to Day  -1])
Randomization (Week 0 [Day  0])
Pre-
surgery , Surgery ,and Post -operative Recovery (Weeks 2 and 3)
Treatment and Assessments(Week 4 through Week 48 [±7 day s])
End of study  (EOS, Week 52 [±7 day s])
Follow -up (telephone contact) 7 (±2) days from the Week 52 (or EOS)
Patients in the no IT treatm ent arm of the pivotal study  will be assessed according to the 
following schedule: 
Screening (Weeks -1 to -4 [Day  -28 to Day  -1])
Randomization (Week 0 [Day  0])
Assessments (Week 4 through Week 48 [±7 day s])
End of study  (EOS, Week 52 [±7 day s])
Follow -
up(telephone contact) 7 (±2) day s from the Week 52 (or EOS) Page 10
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 11The separate substud y is open -label and single arm.  Patients who meet all entry  criteria 
for participation in the substudy will be considered enrolled on Day  0.  Thereafter, 
patients who are enr olled in the separate substudy  will follow the same schedule of study  
visits as idursulfase- IT-treated patients in the pivotal study .  
Patients in the substudy  will be assessed according to the following schedule: 
Screening (Weeks -1 to -4 [Day  -28 to Da y -1])
Enrollment (Week 0 [Day 0])
Pre-surgery , Surgery ,and Post -operative Recovery (Weeks 2 and 3)
Treatments and assessments (Week 4 through Week 48 [±7 day s])
End of study  (EOS, Week 52 [±7 day s])
Follow -up (telephone contact) 7 (±2) day s from the Week 52 (or EOS) 
Patients in both the IT treatment and no IT treatment arms of the study  will complete EOS 
assessments at Week 52 (Visit Month 13).  All patients will participate in a follow -
up 
contact (b y telephone) approximately  7 day s after the EOS visit.
A patient who discontinues or is withdrawn prior to study  completion will be asked to 
participate in an EOS visit within approximately  30 day s after withdrawal or 
discontinuation (EOS assessments for such patients will be the same as Week 52 
assessments), and also to complete a follow up contact approximately  7 day s after the 
patient’s EOS visit.  There is no replacement of patients who do not complete the study.
For details see the stud y Schedules of Events.
The SOPH -A-PORT Mini S IDDD will be used to obt ain cerebrospinal fluid (CSF) 
samples and to deliver all IT injections of idursulfase -IT.  If the IDDD appears to be non-
functional, or if its use is precluded on a scheduled day  of dosing, site personnel will refer 
to the IDDDManual , which provides detai
ls on the investigation and management of an y 
IDDD-related issues.  If the ITspace is not accessible via the IDDD, lumbar puncture may  
be utilized under define d circumstances for administration of idursulfase -IT or to obtain to 
obtain a CSF sample.
Genera l anesthesia /sedation may be required for injections of study  drug and some 
evaluations, and can be used at the discretion of the Investigator .  
A Data Safety  Monitoring Board ( DSMB ) will oversee both idursulfase -ITand device 
safet y.  The D SMB will be notified of IDDD failures and related complications on a 
periodic basis according to the DSMB charter.   
Patients will have the IDDD removed when they discontinue from the study , unless the 
patient is continuing to receive treatment through another mechanism (eg, extension study , 
expanded access program).
Study Duration:
The planned overall duration of each patient’s participation in the study  is approximately  
14 to 15 months from Screening to the last scheduled contact.  
An extension study  is planned durin g which patients who complete HGT -HIT-094 may  
continue to receive IT treatment with idursulfase -IT via the SOPH -A-PORT Mini S 
device.Page 11
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 12Study Inclusion and Exclusion Criteria:
Inclusion Criteria
Patients must meet the following criteria to be considered eli gible for randomization in the 
pivotal study : 
1.The patient is male and is ≥3 and <18 years of age at the time of informed consent.
Note that patients who are younger than 3 years of age may be enrolled in a separate 
substudy provided that they have a docu mented complex rearrangement genotype of 
the iduronate -2-sulfatase gene and meet other inclusion criteria, provided below.
2.The patient must have a documented diagnosis of MPS II.  Of the three criteria below, 
the combinations (1a AND 1b) or (1a 
AND 1c) will be accepted as diagnostic of MPS 
II:
a.The patient has a deficiency  in iduronate -2-sulfatase enzy me activit y of ≤10% of 
the lower limit of the normal range as measured in plasma, fibroblasts, or 
leukocy tes (based on the reference laboratory ’s normal range).
AND
b.The patient has a documented mutation in the iduronate -
2-sulfatase gene that 
leaves the FMR1 and FMR2 genes intact.  In the case of a positive family  history , 
the genoty pe of a brother or uncle (with appropriate informed consent, or assent if 
applicable) may  be accepted as documentation at the discretion of the Medical 
Monitor.
OR
c.The patient has a normal enzy me activity  level of one other sulfatase as measured 
in plasma, fibroblasts, or leukocy tes (based on the normal range of measuring 
laboratory ).
3.The patient has evidence at Screening of Hunter s yndrome -related cognitive 
impairment, defined as follows :
  
Note that separate inclusion criteria with respect to patient cognitive status at 
Screening apply to patients ≥3 and <13 years of age and patients ≥13 and <18 years 
of age.
A patient who is ≥3 and <13 years of age must have one of the followin g criteria (3a 
OR 3b) :
a.A GCA score ≥55 and ≤85 .  
OR
b.
If the patient has a GCA score at Screening >85, there must be evidence of a 
decrease in GCA score of ≥10 points over 12 months from a previousl y 
documented test result in observational study  HGT -HIT-090.
A
patient who is ≥13 and <18 years of age must have both of the following criteria
(3c AND 3d) :Page 12
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 13c.A GCA score of ≥55 and ≤85  
AND
d.There must be evidence of a decrease in GCA score of ≥10 points over 12 months 
from a previousl y documented test result in o bservational study  HGT -HIT-090.
4.The patient has received and tolerated a minimum of 3 months of therapy  with 
Elaprase during the period immediately  prior to Screening.
5.The patient must have sufficient auditory  capacity, with or without hearing aids in the
Investigator ’s judgment, to complete the required protocol testing, and be compliant 
with wearing the aid on scheduled testing day s.
6.The patient’s parent(s) or legally  authorized guardian(s) must have voluntarily  signed 
an Institutional Review Board/Indep endent Ethics Committee approved informed 
consent form after all relevant aspects of the study  have been explained and discussed.  
Consent of the patient’s parent(s) or legall y authorized guardian(s) and the patient’s 
assent, if applicable, must be obtained prior to the start of an y stud y procedures.
Patients must meet all of the following criteria to be considered eligible for enrollment in 
the separate substudy : 
1.The patient is male and is <3years of age at thetime of informed consent.
2.The patient must have a documented diagnosis of MPS II.  Thefollowing two ty pes of 
documentation will be accepted as diagnostic of MPS II:
a.The patient has a deficiency  in iduronate -2-sulfatase enzy me activit y of ≤10% of 
the lower limit of the normal range as measured in plasma, fibroblasts, or 
leukocy tes (based on the reference laboratory ’s normal range)
AND
b.
The patient has a documented complex chromosomal rearrangement of the 
iduronate -2-sulfatase gene that leaves the FMR1 and FMR2 genes intact 
In the case of a positive family  history , the genot ype of a brother or uncle (with 
appropriate informed consent, or assent if applicable) may  be accepted as 
documentation at the discretion of the Medical Monitor.
3.The patient has received and tolerated a minimum of 3 months of ther apy with 
Elaprase during the period immediately  prior to Screening.
4.The patient must have sufficient auditory
 capacity, with or without hearing aids in the 
Investigator ’s judgment, to complete the required protocol testing, and be compliant 
with wearing th e aid on scheduled testing day s.
5.The patient’s parent(s) or legally  authorized guardian(s) must have voluntarily  signed 
an Institutional Review Board/Independent Ethics Committee approved informed 
consent form after all relevant aspects of the study  have b een explained and discussed.  
Consent of the patient’s parent(s) or legall y authorized guardian(s) and the patient’s 
assent must be obtained prior to the start of an y study  procedures. 
Exclusion Criteria
Patients who meet an y of the following criteria ar e not eligible to be randomized into the 
pivotal study  or enrolled in the separate substudy :  
1.The patient has clinicall y significant non -Hunter sy ndrome -related CNS involvement Page 13
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 14(such as Fragile -X syndrome) which is judged b y the Investigator to be likely  to 
interfere with the accurate administration and interpretation of protocol assessments.
2.The patient has a large chromosomal deletion or complex rearrangement genoty pe that 
includes an inactivation and/or deletion of the FMR1 and/or FMR2 genes. 
3.The patie nt has a significant medical or ps ychiatric comorbidity (ies) that might affect 
study  data or confound the integrity  of study  results.
4.The patient has contra -indications for performance of lumbar puncture such as 
musculoskeletal /spinal abnormalities or risk of abnormal bleeding. 
5.The patient has a history  of complications from previous lumbar punctures or 
technical challenges in conducting lumbar punctures such that the potential risks 
would exceed possible benefits for the patient. 
6.The patient has an openi ng CSF pressure upon lumbar puncture that exceeds 30 cm 
H2O.
7.The patient has experienced infusion -related anaphy lactoid event(s) or has evidence of 
consistent severe adverse events related to treatment with Elaprase which, in the 
Investigator’s opinion, ma y pose an unnecessary  risk to the patient.
8.The patient has received a cord blood or bone marrow transplant at an y time or has 
received blood product transfusions within 90 days prior to Screening.
9.The patient has a history  of poorly  controlled seizure disorder.
10.The patient is unable to comply  with the protocol (eg, has significant hearing or vision 
impairment, a clinicall y relevant medical condition making implementation of the 
protocol difficult, unstable social situation, known clinically  significant 
psychiatric/behavioral instability , is unable to return for safet y evaluations, or is 
otherwise unlikel y to complete the study), as determined by the Investigator .
11.The patient is enrolled in another clinical stud y that involves clinical investigation or 
use of any investigational product (drug or [intrathecal/spinal device] device ) within 
30 day s prior to study enrollment or at any  time during the stud y.
12.The patient has an y known or suspected h ypersensitivity  to anesthesia or is thought to 
be at an unacceptably high risk for anesthesia due to compromised airway s or other 
conditions.
13. The patient has a condition that is contraindicated as described in the SOPH-A- PORT 
Mini S IDDD Instructions for Use , including:
a.The patient has had, or may  have, an allergic reac tion to the materials of 
construction of the SOPH -
A-PORT Mini S device
b.The patient’s bod y size is too small to support the size of the SOPH -A-PORT 
Mini S Access Port, as judged b y the Investigator
c.The patient’s drug therapy requires substances known to be incompatible with 
the materials of construction 
d. The patient has a known or suspected local or general infection
e.The patient is at risk of abnormal bleeding due to a medical condition or 
therap y
f.The patient has one or more spinal abnormalit ies that could complicate safe 
implantation or fixation
g.The patient has a functioning CSF shunt device
h.The patient has shown an intolerance to an implanted devicePage 14
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 15Pharmacokinetic Assessments:
Determination of idursulfase concentration in serum and C SF samples.
Pharmacodynamic Assessments:
Determination of the concentration of GAG in CSF samples.
Efficacy Assessments:
Neurodevelopmental status will be assessed over time by  measuring cognitive and 
adaptive functions as follows:
Cognition: t he Differe ntial Ability  Scales, Second Edition (DAS- II) will be used to assess 
all patients randomized in the pivotal study .  For patients participating in the separate 
substudy  only  (ie, patients with a complex rearrangement genot ype of the iduronate -
2-sulfatase ge ne and who are below the age of 3 years) cognition will be assessed initially  
using the Bay ley Scales of Infant Development, Third Edition (BSID
-III).  When these 
patients reach at least 42 months of age, if considered evaluable using the DAS -II 
instrument , they  will transition to use of the DAS -II for continued assessment of 
cognition.
Adaptive Behaviors: the Vineland Adaptive Behavioral Scales, Second Edition (VABS -II) 
will be used to assess all patients. 
Safety Assessments:
Safety  will be assessed by  adverse events (by  type, severit y, and relationship to treatment
[idursulfase -IT, IDDD, device surgical procedure, I T administration process] and IV 
Elaprase infusion ), changes in clinical laboratory  testing (serum chemistry , hematology , 
urinaly sis), phy sical and neurological examination, vital signs, 12- lead ECG , CSF 
chemistries (including cell counts, protein, and glucose), anti -idursulfase antibodies in 
CSF and serum, and determination of antibodies having enzy me neutralizing activity .
SOPH -A-PORT Mini S Device Assessments:
SOPH -A-PORT Mini S assessments will include measures of device implantation, device 
function, device longevity, record of revisions, removals, and replacements of the 
implanted I DDD, and adverse events associated with the device. This data will be 
collected on the patient’s electronic case report form (eCRF) from the time of 
implantation and continue throughout the study  as long as the SOPH-A- PORT Mini S 
remains implanted .
Statistical Methods: 
General Methods 
Continuous variables will be summarized using descriptive statistics (N, mean, standard 
deviation, minimum, median, and maximum).  Categorical variables will be summarized 
using the number and percentage of patients in each category .  Data will be summarized 
with respect to patient disposition, demographic and baseline characteristics and 
concomitant medication use.  The efficacy  endpoints, safet y assessments and other 
outcome results for each treatment group will be summarized descriptively  unless 
otherwise indicated.  In addition, least squares means, p- values and 95% confidence 
intervals for least squares mean treatment differences will also be provided where relevant 
for efficacy  endpoints.  All the hy pothesis tests will be two-sided and will be performed at 
the 0.05 level of significance unless stated otherwise.  Safet y data from the single -arm Page 15
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 16substudy  will be summarized separatel y and efficacy data will be listed. 
Analy sis Populations 
For the pivotal trial, all efficacy  data anal yses will be performed using the Intent -to-Treat 
(ITT) Population, which is defined as all randomized patients.  
All safet y data anal yses will be performed using the Safet y Population, which is defined 
as all randomized patients with any  post -randomization safet y assessments.  Device 
related anal yses will be conducted in the treated subset of the Safet y Population who had 
the device implant procedure performed.
All PK data anal yses will be performed using the PK population. The PK population will 
be defined as all patients who received study  drug a nd had at least one sample collected 
for pharmacokinetic analy sis.
For the substud y, all analyses will be performed on the Substudy  Population, defined as 
all patients enrolled and treated with stud y drug in the substudy. 
Analy sis of Efficacy
For the pivotaltrial, the primary  efficacy  endpoint is the change from study  baseline 
(Screening V isit) to Visit Week 52 in the General Conceptual Ability  (GCA) score as 
measured b y the DAS -II.  The primary  anal ysis will compare the treatment groups using a 
linear m ixed model repeated measures (MMRM) analy sis.  The repeated measures are the 
change from baseline GCA scores obtained at the scheduled Visit Weeks 16, 28, 40, and 
52, respectivel y.  The model will include fixed categorical effects for treatment, visit 
week , treatment by  visit week interaction, and a GCA classification factor (based on 
baseline GCA score ( ≤70 or>70) and the GCA classification factor b y treatment 
interaction.  The GCA classification factor by treatment interaction term will be included 
in the model if the interaction is significant at the 10% level; otherwise, the MMRM 
analysis without this interaction will be considered the final primary  model. From this 
model, least squares means, standard errors, treatment differences in least squares mea ns, 
and 95% confidence intervals and p -values will be estimated for each time point.  Primary  
inference is based on the treatment comparison at Visit Week 52 from this model. 
The key  secondary  efficacy  endpoint is the change from study  baseline ( Screening Visit) 
to Visit Week 52 in the Adaptive Behavior Composite (ABC) score as measured b y the 
VABS -II. This endpoint will be anal yzed using an MMRM analy sis with effects of 
treatment, visit week, treatment by visit week interaction and the baseline ABC score as a 
continuous covariate. The baseline ABC score by  treatment interaction will be included 
in the model if the interaction is significant at the 10% level; otherwise, the MMRM 
analysis without this interaction will be considered the final model for this endpoint.   The 
inferential test of the key secondary  endpoint is based on the treatment comparison at 
Visit Week 52 from this model.
The overall ty pe I error rate for tests of the primary and key  secondary  endpoints will be 
controlled at 0.05.  To control an overall type I error rate at this level for the two tests, a 
fixed sequential testing procedure will be followed.  The null hy pothesis of no treatment 
difference for the primary  endpoint will be tested first.  The null hypothesis of no 
treatment differ ence for the key  secondary  endpoint then may  only be rejected if the null 
hypothesis for the primary  endpoint is first rejected.Page 16
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 17The following secondary efficacy  endpoints will be anal yzed using an MMRM analy sis in 
the same manner as described above for th e key  secondary  endpoint with the continuous 
covariate corresponding to the baseline score for each measure: 
(1) The change from baseline to Visit Weeks 16, 28, 40, and 52 in standardized scores in 
cluster areas of the DAS -II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite 
(SNC) 
(2) The change from baseline to Visit Weeks 16, 28, 40, and 52 in the standardized 
domain scores of the VABS -II: Communication, Daily Living Skills, Socialization, Motor 
Skills, and Maladaptive Behavior.  
All other s econdary  efficacy  endpoints will be summarized descriptively  by treatment 
group. Mean values by  treatment group will plotted over time.
Analy sis of Safet y 
All safet y anal yses will be descriptive. Adverse events will be summarized by  treatment 
group, bot h overall and within sy stem organ class by  preferred term. Adverse events will 
also be tabulated b y highest severit y (mild, moderate, severe) and b y closest relationship 
to study  drug (not related, related) for treated patients. Separate tabulations will be 
provided for adverse events related to IV Elaprase infusion, the IDDD, device surgical 
procedure ,and the IT-administration process .  
The proportion of patients with at least one IDDD failure and the proportion with 
malfunction only , as well as the nu mber of and reasons for IDDD failures and 
malfunctions will be summarized.  The rate of IDDD failures and malfunctions and the 
corresponding 95% confidence interval will also be estimated.  The time from initial 
implant surgery
 to first IDDD failure and the time to first malfunction only will be 
analyzed using Kaplan-Meier Life Table methods.  
Laboratory  values in serum and CSF components, vital signs, ECG parameters and other 
safet y assessments will be summarized by treatment group. The number and percen tage 
of patients testing anti -idursulfase antibody  positive and negative at each time point will 
be summarized. 
All safet y data from the separate substudy will be similarly  summarized in a descriptive 
manner.
Date of Original Protocol: 04April 2013 Page 17
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 18LIST OF ABBREVIATIONS AND DEFINITIONS OF T ERMS
Term Definition
ABC adaptive behavior composite
AE adverse event
ALT alanine aminotransferase (SGPT)
AP alkaline phosphatase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
BMI body mass index
BP blood pressure 
BUN blood urea nitrogen
C Celsius
CBC complete blood count
cc cubic centimeter(s)
CFR Code of Federal R egulations
cGMP Current Good Manufacturing Practices
CI confidence interval
CK creatine kinase
Cmax maximal concentration
cm centimeter(s)
CNS central nervous system
CO 2 total carbon dioxide
CRO contract research organization
CSF cerebrospinal fluid
CV coefficient of variation
DAS -II Differential AbilityScales, Second Edition
dL deciliter
DQdevelopme ntal quotient
DSdermatan sulfate
DSMBData Safety Monitoring Board
ECG electrocardiogram
eCRF electronic case report form
EOS end of study
EQ-5D EurolQol -5D instrument for use as a measure of health outcome
ERT enzyme replacement therapyPage 18
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 19Term Definition
EU Europe an Union
F Fahrenheit
FDA United States Food and Drug Administration
g gram(s)
g/dL grams per deciliter
GAG glycosaminoglycans
GCA general conceptual ability
GCP Good Clinical Practice
GGT gamma glutamyl transferase
GLP Good Laboratory Practices
Hb hemoglobin
Hct hematocrit
Hgb hemoglobin
HGT -2310 Drug code name for formulation of recom binant iduronate-2- sulfatase (idursulfase) 
for intrathecal administration 
HPLC highperformance liquid chromatography
hr hour(s)
I2S iduronate -2-sulfatase
IB Investigator’s Brochure
ICH International Conference on H armonisation
ICP intracranial pressure
IDDD intrathecal drug delivery device
IEC Independent Ethics Committee
IFU Instructions for Use
Ig immunoglobulin
IND Investigational New Drug applicat ion
IRB Institutional Review Board
IT intrathecal
ITT intent -to-treat
IV intravenous(ly)
IVR interactive voice response
kg kilogram(s)
L liter(s)
LDH lactic dehydrogenase
m meter(s)Page 19
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 20Term Definition
M6P mannose -6-phosphate
MCH mean corpuscular hemoglobin
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activity 
min minute(s)
mL milliliter(s)
mm millimeters
mM millimolar
MMRM mixed model repeated measures
MPS II Mucopolysaccharidosis II (Hunter syndrome)
MRI magnetic resonance imaging
MRT mean residual time
n number
N or n number of observations
NCI CTC National Cancer Institute Common Toxicity Criteria
NDA New Drug Application
ng nanogram(s)
PD pharmacodynamic
PK pharmacokinetic(s)
PRO patient reported outcome
PT prothrombin time
PTT partial thromboplastin time
QTc corrected QT  interval
RBC red blood cell(s)
SAE serious adverse event
SAP statistical analysis plan
SAS Statistical Analysis System©
SD standard deviation
SE standard error 
SGOT serum glutamic oxaloacetic transaminase (ast)
SGPT serum glutamic pyruvic transaminase (alt)
SGSS Shire Global S afety System
Shire HGT Shire Human Genetic Therapies, Inc.
SNC special nonverbal composite
SOC system organ classPage 20
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 21Term Definition
SOE schedule of events
SOPH -A-PORT
Mini SSOPH -A-PORT®Mini S, Implantable Access Port, Spinal, Mini Unattached, w ith 
Guidewire
T4 thyroxine
U unit(s)
UADE unanticipated adverse device effect
ULN upper limit of normal
US United States
Vss apparent volume of distribution at steady state 
VAS visua l analog scale
VABS -II Vineland Adaptive Behavior Scales, Second Edition
WBC white blood cell count
WHO -DD World Health Organization Drug DictionaryPage 21
idursulfase-IT 
SOPH-A-PORT® Mini S 
Clinical Trial Protocol: HGT-HIT-094 04 April 2013  
Shire Confidential 22 1 INTRODUCTION 
1.1 Mucopolysaccharidosis II (Hunter syndrome) 
Mucopolysaccharidosis II (MPS II) is a rare, X-lin ked, inherited disease that affects males nearly 
exclusively.  Its estimated incidence is 1 in approximately 162,000 live births. 1, 2  Though 
typically appearing normal at birth, all MPS II patients suffer from a progressive, serious, 
life-limiting disease.3, 4   
The disease is caused by the absence of, or deficiency in, the activity of the lysosomal enzyme, iduronate-2-sulfatase (I2S) which acts to cleave O-linked sulfate moieties from the 
glycosaminoglycan (GAG) molecules de rmatan sulfate and heparan sulfate.
5  Insufficient 
activity of I2S leads to progressive accumulation of  GAG in nearly all organs and body tissues.   
The central underlying pathophysiologi cal process leading to the clin ical manifestations of MPS 
II is the chronic accumulation of dermatan sulfate and heparan sulfate inside cellular lysosomes, resulting in cellular engorgement, organom egaly, tissue destruction, and organ system 
dysfunction.  Accumulation of GAG affects nearly all cell types, tissues, and organs of the body 
including the respiratory tract,  heart, liver, spleen, leptomen inges, bones, joints, oropharynx, 
head, neck, and CNS.
6  Clinical manifestations include severe airway obstruction, skeletal 
deformities, cardiomyopathy and, in most  patients, neurological decline.7  Death may occur in 
the first or second decade of life.   Less affected patients may surv ive into adulthood, with airway 
obstruction and cardiac causes of ten contributing to death.4 
Phenotypic expression of the diseas e spans a wide spectrum of clinical severity.  However, two 
extremes at either end of the continuum of MPS II have been identified based on cognitive status.
4, 8  The first is broadly characterized as an “attenuated” or milder form in which 
intellectual and neurodevelopmen t faculties are largely intact , although somatic pathology is 
present.  The term “severe” has been adopted to describe a second br oad phenotype of MPS II 
patients who suffer from neurodevelopmental impair ment in addition to so matic manifestations 
of the disease.  It has been estimated that  67 to 77% of MPS II patients will develop CNS 
involvement and be char acterized as “severe.8  Despite these characterizations, patients with 
predominantly somatic involvement may neverthe less have a life-limiting disease course.   
Although there is heterogeneity with respect to disease progr ession, the onset of signs and 
symptoms typically occurs at about 3 years of age.6, 9  An earlier appearance of clinical 
symptoms generally, but not always, predicts a more severe clinical course.4-6, 10  Knowledge of 
the genotype is of limited value in predicting a pa tient’s clinical course with respect to CNS 
involvement.  An exception is represented by ch ildren with complete absence of functional 
enzyme due to complex chromosomal rearrangeme nts in the iduronate-2-sulfatase gene, who 
invariably develop severe neurodevelopmental impairment.11, 12 
1.2 Unmet Medical Need 
The currently approved therapy for Hunter syndrome is Elaprase® (idursulfase), recombinant 
human iduronate-2-sulfatase for intravenous (IV) administration.  Elaprase has provided clinical Page 22
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 23benefit with respect to somatic pathologies in patients with Hunter s yndrome, and has a well
characterized safet y profile.  Although man y of the physical s ymptoms of the disease can be 
reduced or eradicated by IVenzy me replacement , 13-15Elaprase has not been evaluated 
specificall y regarding its independent quantifiable impact on CNS pathology, due to the 
acknowledged impermeabili ty of the blood -brain barrier to macromolecules such as idursulfase.  
In addition, Elaprase is formulated for IV use only and is contraindicated for direct injection into 
the CNS.  Thus, no specific therap y exists for the CNS pathologies of Hunter s yndrome .  
A distinct formulation, designated idursulfase -IT (HGT -2310), was developed specifically  for 
delivery  into the cerebrospinal fluid (CSF) via intrathecal (IT) administration to access CNS 
tissues and overcome macromolecular distribution limits imposed b y the blood- brain barrier.  
The active ingredient of the idursulfase -IT product [recombinant human iduronate -2-sulfatase] is 
the same active ingredient as in commerciall y available Elaprase.  In contrast to Elaprase, 
however, idursulfase -IT is specially  formulated for, and compatible with, direct introduction into 
the IT space, 
since it is isotonic and contains excipients suitable for IT use.
In order to traverse the blood -brain barrier, Shire HGT is evaluating delivery  of idursulfase -IT 
directly  into the CNSusing an intrathecal drug delivery  device (IDDD) , the SOPH -A-PORT®
Mini S, I mplantable Access Port, Spinal, Mini Unattached, with Guidewire (SOPH -A-PORT
Mini S) . The advantage of using an IDDD is the potential to obviate the need for multiple 
lumbar pu nctures for drug delivery . 
1.3 Overview of Results of Phase I/II Studies 
The safet y and tolerability of ascending doses (1, 10, or 30 mg) of intrathecally  administered 
idursulfase -IT were investigated in the first -in-human study  HGT -HIT-045, a randomized, open -
label, no- treatment controlled Phase I /II stud y in which idursulfase -IT was administered once 
monthly  to pediatric MPS I I patients via a surgically  implanted IDDD ( PORT -A-CATH®II Low 
Profile™Intrathecal Implantable Access S ystem [PORT -A-CATH]) for 6 months in conjunction 
with once weekly  IVinfusion of Elaprase.  Eligible patients who completed HGT- HIT-045 are 
continuing to receive monthly  ITinjections of idursulfase -IT,in conjunction with Elaprase 
therap y,in extension study  HGT -HIT-046.  Across the HGT -HIT-045 and HGT -HIT-046 
studies, long -term safet y, pharmacokinetics, and pharmacod ynamics (effect on GAG 
concentration in CSF) have been evaluated .  Effects of IT administration of idursulf ase-IT on 
neurodevelopmental health ha
ve been evaluated using standardized tests of cognitive and 
adaptive functions.
Based on the data available from HGT- HIT-045 and HGT -HIT-046, idursulfase -IT has been 
found to be well tolerated at all doses administered without safety  concerns related to the study  
drug.  There have been no deaths or discontinuations due to adverse events in either study , and 
no serious adverse events related to idursulfase -IT. T
hemajority  of serious adverse events in
both studies have been associated with the PORT -A-CATH device , and designated as serious 
because of the requirement for overnight hospitalization for surgical revision/removal of the 
IDDD.  The events related to the use of the IDDD included surgical removal and replacement of 
the device because of mechanical failures, primarily connector pin breaks and catheter slippage, Page 23
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 24to overnight admissions to the clinical site for a suspected device infection, and device removal 
because of wound issues.  
As a result of the device -related concerns inthe Phase I/II program, additional guidelines and 
training materials were developed for implanting neurosurgeons concerning the surgical 
implantation of the IDDD , and repeated lumbar punctures were permitted per protocol 
amendment as a means of IT delivery  of study  drug in the event of device malfunction .  To 
address the frequent occurrence of device failures observed with use of the PORT -
A-CATH
IDDD in the Phase I/II studies, the SOPH -A-PORT Mini S will be used in this Phase II /III study .  
The SOPH -A-PORT Mini S device is intended to address the frequent occurrence of device 
failure s observed with use of the PORT -A-CATH IDDD in the Phase I/II studies .
Intrathecal administration of idursulfase -IT to MPS II patients in HGT -HIT-045 and 
HGT -HIT-046 at the 10 and 30 mg dose regimens resulted in a pronounced pharmacod ynamic 
reduction from baseline in the concentration of GAG in CSF; the 1 mg dose regimen induced a 
slower and less pronounced reduction in GAG concentration in CSF.  Available results o f 
neurodevelopmental assessments performed across HGT -HIT
-045 and HGT -HIT-046 suggest 
the potential of intrathecal delivery  of idursulfase -IT to halt or slow the progressive decline in 
neurodevelopmental status in this patient population.  Several patients at earlier stages of 
cognitive decline who received treatment with idursulfase -IT at the 10 mg and 30 mg doses 
showed evidence of stabilization orimprovement of cognitive and adaptive functions.
1.3.1 Rationale for Current Phase II/III Study
Because intravenousl y administered idursulfase cannot traverse the blood- brain barrier due to its 
impermeability  to large macromolecules such as proteins, the re is an unmet medical need in the 
population of MPS II patients with CNS disease to support clinical development of idursulfase -
IT for intrathecal use.  
TheSOPH -A PORT Mini S 
delivery  device will be used for IT administration of idursulfase -IT 
to MPS II patients 
in this study .  In contrast to IT administration via lumbar puncture, the use of 
anIDDD does not always r equire full anesthesia ; inmany  cases, sedation may  be appropriate.  
Multiple drug administrations, therefore, may  require only  a single episode of general anesthesia 
(for device implantation), in contrast to the multiple episodes of general anesthesia tha t would be 
required for repeated lumbar punctures in this patient population.   
Nonclinical experience with I T administration of idursulfase -IT has demonstrated wide 
distribution of idursulfase to the CNS tissues.  I dursulfase -IT has been shown to be well tolerated 
in several species and to be active in a murine disease model of idursulfase deficiency . 
In Phase I/II clinical studies in MPS II patients, idursulfase- IT has been generall y well tolerated.  
Stabilization or improvement in cognitive and adaptive functions has been noted in some of the 
children enrolled in the trials .  The available data support the Sponsor’s hy pothesis that a 
therapeutic benefit may  be expected in MPS II children with cognitive impairment.   
The therapeutic strategy
 consisting of idursulfase -IT administered intrathecally  via the 
SOPH -A-PORT Mini S device and concomitant IV Elaprase therapy  is intended to address both Page 24
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 25the CNS and somatic manifestations of Hunter s yndrome.  Idursulfase -IT is intended for l ong-
term treatment of Hunte r syndrome in patients with cognitive impairment to slow progression of 
cognitive and functional impairment.
The design of the proposed study , including the neurodevelopmental assessment tools and 
endpoints, and the selection of idursulfase -IT 10 mg dose,have been informed by the results of 
Phase I /II studies HGT -HIT-045 and HGT -HIT-046 (S ee Section 1.3).  Please refer to the current 
edition of the Investigator’s Brochure for additional information concerning the safet y and 
clinical development of idursulfase -ITand for information concerning the SOPH -
A-PORT Mini 
Sdelivery  device . Page 25
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 262STUDY OBJECTIVES
The treatment regimen is defined as o nce monthly (ie, every  28 day s) intrathecal administration 
of idursulfase -IT 10 mg for 12 months via a surgically  implanted IDDDor lumbar puncture.
2.1 Primary Objective
The primary  objective of this study  is:
To determine the effect of the treatment regimen in pediatric patients with Hunter 
syndrome and earl y cognitive impairment on the General Conceptual Ability  (GCA) 
score as measured b y the DAS -II, in conjunction with Elaprase therap y
2.2 Secondary Objective s
The key secondary objective of this study  is:
To determine the effect of the treatment regimen in pediatric patients with Hunt
er 
syndrome and earl y cognitive impairment on the Adaptive Behavior Composite (ABC) 
score as measured b y the VABS -II,in conjunction with Elaprase therapy
The secondary  objectives of this study  are:
To determine the effect of the treatment regimen in pedi atric patients with Hunter 
syndrome and earl y cognitive impairment, in conjunction with Elaprase therap y, on:
oCognitive function as measured b y the cluster areas and subtests of the DAS -II
oAdaptive behavior as measured b y the domains of the VABS -II
2.3 Safety Objectives
To determine the effect of the treatment regimen on safet y as assessed b y adverse events, 
clinical laboratory  testing, phy sical examination findings, vital signs, and 
electrocardiogram (ECG) recordings
To evaluate the anti- idursulfase antibody  response in serum and CSF during the treatment 
regimen
2.4 SOPH
-A-PORT Mini S Device Objectives:
To determine the safety and performance of the SOPH -A-PORT Mini S devicePage 26
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 272.5 Pharmacokinetic and Pharmacodynamic Objective s
The pharmacokinetic (PK) and pharmacod ynamic (PD) objectives of this study  are:
To evaluate the concentration of idursulfase in serum and cerebrospinal fluid (CSF) after 
ITadministration and determine pharmacokinetic parameters
To determine the effect of the treatment regimen on the concentratio n of 
glycosaminogl ycan (GAG) in CSF
2.6 Health Status Objective
To evaluate health status as measured b y the EQ -5D instrument
2.7 Substudy Objective
The objective of the substudy  is:
To examine the effect of the treatment regimen in pediatric patients with Hun ter 
syndrome <3 y ears old and having a complex rearrangement genot ype of the 
iduronate -2-sulfatase gene on safet y and efficacy  mea suresPage 27
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 283STUDY ENDPOINTS
3.1 Primary Efficacy Endpoint
The primary  efficacy  endpoint of this study  is:
Change from baseline in the GCA score after 12 months of treatment, at Visit Week 52, 
as obtained b y DAS -II testing
3.2 Secondary Efficacy Endpoint s
The key secondary efficacy  endpoint of this study  is:
Change from baseline in the ABC score after 12 months of treatment at Visit Week 52 , as 
obtained by  VABS -II testing
The secondary  efficacy  endpoints of this study  are:
Change from baseline to Visit Weeks 16, 28, and 40 in the GCA score as obtained by 
DAS -II testing
Change from baseline to Visit Weeks 16, 28 ,and 40 in the ABC score as o btained by  
VABS -II testing
Change from baseline to Visit Weeks 16, 28, 40, and 52in standardized scores in cluster 
areas of the DAS -
II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite 
(SNC)
Change from baseline to Visit Weeks 16, 28, 40, and 5 2 in the standardized domain 
scores of the VABS -II: Communication, Daily  Living Skills, Socialization, Motor Skills, 
and Maladaptive Behavior
Change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents and 
development quotient (DQ) for th e subcategories of the DAS -II (Verbal Comprehension, 
Picture Similarities, Naming Vocabulary , Pattern Construction, Matrices
,and Copy ing 
for the DAS -II/Early Years, and Recall of Designs, Word Definitions, Pattern 
Construction, Matrices, Verbal Similariti es,and Sequential and Quantitative Reasoning 
for the DAS -II/School Years)
Change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents and 
developmental quotients of the VABS -II: Communication, Daily Living Skills, 
Socialization, Motor Sk ills, and Maladaptive Behavior
3.3 Pharmacokinetic and Pharmacodynamic 
Endpoint s
The PK and PD endpoint s of this study  are:
Serum and CSF 
concentration of idursulfase and serum pharmacokinetic parameters after 
IT administration
Change from baseline in the concentration of GAG in CSF Page 28
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 293.4 Safety Assessments
Safety  will be assessed during the study  by collection of adverse events (b y type, severit y, and 
relationship to treatment [ idursulfase -IT, the IDDD, device surgical procedure, or IT 
administration process ]andIV Elaprase infusion ), changes in clinical laboratory
 testing (serum 
chemistry , hematology , urinaly sis), phy sical and neurological examination, vital signs, 12- lead 
ECG , CSF chemistries (including cell counts, protein, and glucose), anti -idursulfase antib odies 
in CSF and serum, and determination of antibodies having enzy me neutralizing activity .
3.5 SOPH-A- PORT Mini S Device Assessments
SOPH -A-PORT Mini S assessments will include measures of device implantation, device 
function, device longevity, record of rev isions, removals, and replacements of the implanted 
IDDD, and adverse events associated with the device. This data will be collected on the patient’s 
electronic case report form (eCRF) from the time of implantation and continue throughout the 
study  as lon g as the SOPH-A- PORT Mini S remains implanted.
3.6 Health Status Assessment
Health status dimensions as obtained b y the EQ- 5D questionnaire .Page 29
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 304INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan
This is a controlled, randomized, two-arm, open -label, assessor -blinded, multicenter study  to 
determine the effect on clinical parameters of neurodevelopmental status of monthly  IT 
administration of idursulfase -IT 10 mg for 12 months in pediatric patients with Hunter sy ndrome 
and cognitive impairment who have previously  received and tolerated a minimum of 3 months of 
therap y with Elaprase.  
All patients will continue to receive Elaprase therapy  as standard of care throughout the study .  
The pivotal study  design is “no I T treatment -controlled” in that 28 patients are ass igned 
randomly  to receive ITtreatment and 14 patients are assigned randomly
 to participate without 
receiving ITtreatment.
Those patients randomized to the IT treatment arm will undergo surgical implantation of the 
SOPH -A-PORT Mini S IDDD followed b y a post-operative recovery  period of at least 14 day s 
prior to the first IT administration of idursulfase- IT.  Treated patients will then receive 12 
monthly  IT injections of 10 mg idursulfase -IT corresponding to a treatment and assessment 
interval of 13 (28- day) months from randomization to the end -of-study  (EOS) evaluations.  
Likewise, patients randomized to the no I T treatment arm will be assessed over 13 (28- day) 
months after randomization.
The separate substud y is open label and single arm.  
4.1.1 Intrathecal Dr ug Delivery 
The study  drug , idursulfase -IT (HGT -2310) will be administered to patients via the 
SOPH -A-PORT®Mini S, I mplantable Access Port, Spinal, Mini Unattached, with Guidewire 
(SOPH -A-PORT Mini S) , manufactured b y Sophysa SA (Orsay, France) or ,alternativel y,via 
lumbar puncture in the event of device malfunction .  ThisIDDD will be used to obtain 
cerebrospinal fluid (CSF) samples and to deliver all IT injections of idursulfase -IT.  
If the IDDD appears to be non -functional, or if its use is precluded on a scheduled day  of dosing, 
site personnel will refer to the IDDD Manual , which provides details on the investigation and 
management of an y IDDD -
related issues.  This includes possible partial revision or complete 
replacement of the IDDD as indicated.  If the intrathecal space is not accessible via the IDDD, 
study  drug may  be administered to a patient by lumbar puncture up to 12 times.  Should the 
IDDD become clogged, undergo mechanical complications, or otherwise not be accessible, the 
CSF sample may  also be obtained from a patient by lumbar puncture up to 12 times.
General anesthesia /sedation may be required for injections of study  drug and some evaluations, 
and may be used at the discretion of the Investigator.  Page 30
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 31A Data Safety  Monitoring Board (DSMB) will oversee both idursulfase -ITand device safet y.  
The D SMB will be notified of IDDD failures and related complications on a periodic basis 
according to the D SMB charter (See Section 11.8).  
Patients will have the IDDD removed when they  discontinue from the study , unless the patient is 
continuing to receive treatment through another mechanism ( eg,extension study , expanded 
access program ).
See Section 13for the Sche dule of Events for the pivotal study (Appendix 1 and Appendix 2 ) 
and separate substud y (Appendix 3).
4.2 Rationale for Study Design and Co mparator Group
Hunter s yndrome (MPS II) is an X -linked genetic disease that occurs predominantly  in males; 
affected females are exceedingl y rare .  The primary  analy sis of efficacy  in th e pivotal study  will 
focus on pediatric MPS II patients (
[male ] ≥3 and <18 years of age) with evidence of cognitive 
impairment.  Note that for the purpose of this study, cognitive impairment is defined as a 
Differential Ability  Scales, Second Edition [DAS -II]16General Conceptual Ability  [GCA] 
standard score at Screening between 85 and 55.  Patients with a GCA score at Screening >85 
who are between 3 and 12 y ears of age may  still be eligible to participate if there is demonstrated 
evidence of a decrease in GCA score of ≥10 points within a 12-month period in observational 
study  HGT -HIT-090.  
Eligible patients will be assigned randomly  to either the monthly  IT injection of 10 mg 
idursulfase -IT group or to the no treatment group in a 2:1 allocation ratio.  The randomization 
scheme will be stratified by  the baseline GCA score (≤ 70 or >70).  The duration of treatment will 
be 12 months, based on 12 consecutive monthly  IT injections in the treated group.  The treated 
patients will be implanted with a SOPH -
A-PORT Mini S IDDD with the intent that idursulfase -
IT will be administered via this I DDD.  However, in case of IDDD malfunction, the drug may  
also be administered via lumbar puncture (refer to Se ction 4.1.1 ). 
The intrathecally  administered dose of idursulfase -IT (10 mg) to be used in this study and the 
treatment regimen were based on findings from studies HGT- HIT-045 and HGT -HIT-046 (See
Section 4.2.1 ).
The comparator group in this study is randomized to “no IT treatment .”  Surgical implantation of 
a device, performance of sham injections, and use of a placebo control were not considered 
appropriate for this group for ethical reasons.
All patients will receive standard -of-care treatment with Elaprase during the study .  Elaprase will 
not be provided b y the Sponsor, but rather will be prescribed b y the patient’s phy sician in 
accordance with local prescribing inf ormation.
The endpoints will be clinical in nature, namely , changes in cognitive and adaptive functioning 
over time. The proposed primary  efficacy  endpoint is the change from baseline in the GCA 
score after 12 months of treatment at Visit Week 52 as obtai ned b y DAS -II testing and a 
comparison of treated versus untreated 
patients will be performed .  This primary  endpoint was Page 31
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 32chosen because of its clinical relevance .  Data from the scientific literature concerning the rate of 
cognitive decline in children wi th MPS II9, 17and the Sponsor’s clinical trial experience with 
cognitivel y impaired MPS II patients suggest that an annual 11 to 14 point drop in GCA may  be 
expected in the absence of an effective treatment.  Thec
hange from baseline in GCA score after 
12 months of treatment is a suitable endpoint for the development of idursulfase -IT in the 
proposed indication , and a 10 to 11 point difference compared with control in mean GCA change 
over that time frame represent sa clinicall y meaningful benefit to patients. Secondary  efficacy  
measures proposed include tests for activities of daily living using the Vineland Adaptive 
Behavior Scales, Second Edition [VABS -II]).18  The proposed key  secondary  efficacy  endpoint 
is the change from baseline in the adap tive behavior composite (ABC) score after 12 months of 
treatment at Visit Week 52 as obtained b y VABS -II testing and a comparison of treated versus
untreated patients will be performed .
Given that 
the pivotal study  will enroll onl y those patients with earl y cognitive impairment, it is 
expected, based on the Sponsor’s Phase I/II experience, that such children will be able to 
complete serial neurodevelopmental assessments using the DAS -II and VABS -II assessment 
tools.
As discussed in Section 1.1, the age distribution of cognitive and functional impairment in 
MPS II indicates that cognitive deficit begins to become quantifiable at around the age of 3 
years.9, 10  By the time a child with MPS II is 12 years old, he is t ypicall y either at the final stages 
of the neurodegenerative process or has largel y escaped cognitive impairment.  This was 
confirmed b y the data from Phase I /II stud y HGT -HIT
-045, where the patients with the mild est 
and earliest forms of cognitive impairment were in the age range of 3 to 7 years.  There are two 
exceptions to this general pattern.  In rare cases, cognitive and functional 
impairment may  be 
noticeable prior to the age of 3 years.  This is observed in children with a complex rearrangement 
of the iduronate -2-sulfatase gene who are at the severe end of the spectrum both for phy sical and 
CNS disease.  Even more rarel y,children may  exhibit a slow progression of CNS disease.9, 12  
Such patients may  have measurable cognitive and functional abilities in
totheir mid teens.  MPS 
II patients within these two categories who are < 3 y ears of age or are ≥13 to <18 y ears of age
may be eligible for participation in HGT- HIT-094 and are discussed infurther detail below. 
Children with a complex rearrangement of the iduronate-2- sulfatase gene represent a special 
subgroup of MPS II patients.  Such cases t ypicall y arise in families where an older sibling has 
been diagnosed with Hun ter sy ndrome and where a high awareness of the disease exists.  These 
rare patients ( ≤20 % of all MPS II patients) invariably  develop cognitive impairment, sometimes 
even before the age of 3 years.  Such patients, if identified prior to 3 years of age ,are ineligible 
to be part of the pivotal study  and will not be rand omized, but rather, will be enrolled into a 
separate substudy
 to receive IT treatment with idursulfase -IT.  Because the primary  assessment 
tool of the pivotal study , the DAS -II, is not suitable for the evaluation of these younger children, 
a more suitable tool, the Bay ley Scales of Infant Development (BSID -III)
,19will be used.  As 
these children will be identified infrequentl y, no enrollment target will be implemented.  The 
analysis of substudy  data will be descriptive onl yand will not be part of the efficacy  anal ysis of 
the pivotal study .  Like patients in the pivotal study, the patients in the substudy will receive 
concomitant therap y with Elaprase.Page 32
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 33Children older than 12 years old with slowly  progressing CNS disease were not identified in 
study  HGT -HIT-045 or in conversations with MPS II experts, but have been described 
sporadically in the literature.9, 12  It is a reasonable hy pothesis that the clinical course in these 
children with an attenuated disease subt ype ma y be different from the t ypical course of 
neurodevelopmental decline.  To mitigate this risk, child ren over 12 years of age with cognitive 
impairment, should they  be identified during the enrollment period of this trial, will be required 
to have shown a decrease in GCA of at least 10 points over a 12
-month period in the 
observational study  HGT -HIT-090 a nd to have a DAS -II GCA standard score at Phase II/ III 
study  entry  between 85 and 55.  These criteria will be implemented to ensure that the clinical 
course of cognitive decline in these children is similar in rate to that in children, for whom the 
cogniti ve decline manifested earlier, thereby  ensuring a more homogeneous target population for 
the trial .  If these and other eligibility  criteria are met, such patients will be randomized (2:1) to 
receive IT treatment with idursulfase -IT or no IT treatment in t he pivotal study .  
4.2.1
Rationale for Dose Selection
Extrapolation to humans from data in non -human primates suggests that a dose from 5 to 35 mg 
delivered intrathecall y would result in sufficient exposure to potentially  elicit a clinical treatment 
response in MPS II patients.  The selection of the 10 mg dose of idursulfase- IT to be given in this 
study was further informed by  the pharmacokinetic and pharmacody namic data of Phase I/II 
studies, HGT -HIT-045 and HGT -HIT-046.
The serum pharmacokinetic profiles of id ursulfase -IT were dose proportional with respect to 
Cmaxbetween the 1 mg and 10 mg idursulfase IT dose groups.  However, the 10 and 30 mg 
idursulfase -IT groups exhibited overlapping serum concentration -time profiles indicative of 
saturation of the transpo rt processes from the CSF to the serum and CNS tissue compartments.  
The pharmacod ynamic properties of idursulfase IT were evaluated in HGT -HIT-045 and 
HGT -HIT-046 by  measuring GAG concentration in CSF at 1 month after each idursulfase -IT 
administration. Compared with the 1 mg idursulfase -IT dose, the 10 mg and 30 mg doses 
produced equivalent, sustained reductions of CSF GAG concentrations.  No appreciable change 
in CSF GAG concentration was observed in the untreated group (note that patients in this grou p, 
as well as the treated group, received weekly  Elaprase infusions throughout the study ).  Thus, the 
pharmacod ynamic profiles associated with monthly idursulfase -IT administration indicated that 
the 1 mg dose was suboptimal, with the 10 mg dose achieving maximal pharmacod ynamic 
response and the 30 mg dose demonstrating no appreciable added benefit.  This response 
correlates with the therapeutic dose range (5 to 35 mg) estimated from evaluation of HGT -2310 
in non -human primates.
The doses (1, 10 , 30 mg) of idursulfase -IT evaluated in the Phase I/II studies demonstrated 
equivalent safety  profiles.  The clinical pharmacokinetic and pharmacody namic profiles of 
idursulfase -IT in MPS II patients indicated that the 10 mg dose provides a maximum 
pharmacologic respo nse.  Therefore, the 10 mg dose of idursulfase -IT was selected for Phase 
II/III investigation in this study .Page 33
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 344.3 Study Duration
The planned overall duration of each patient’s participation in the study  is approximately  14 to 
15months from Screening to the las t scheduled contact.  
An extension study  is planned during which patients who complete HGT
-HIT-094 may  continue 
to receive IT treatment with idursulfase -IT via the SOPH -A-PORT Mini S device.Page 34
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 355STUDY POPULATION SEL ECTION
5.1 Study Population
For the pivotal stud y, it is planned that 42 patients (28 treated , 14 untreated ) with earl y cognitive 
impairment who are ≥3 to <18 y ears of age at the time of informed consent and meet all study  
entrance criteria will be randomized.  Note that, to meet study  entry  criteria, p atients who are 
≥
13 to <18 years of age at the time of informed consent must have documented evidence of 
cognitive decline over 12 months in observational study  HGT -HIT
-090 in order to participate in 
this study .
A separate substudy  willenroll patients who have a complex rearrangement genot ype in the 
iduronate -2 sulfatase gene and who are below the age of 3 y ears at the time of informed consent.  
Such patients are ineligible for the pivotal study  and will not be randomized, but may  receive 
treatment with id ursulfase -IT in the substud y.  In view of the rarity of such patients, no 
enrollment target will be proposed.  The enrollment of patients below 3 y ears of age into this 
separate substudy  will be considered additional to the 42 patients planned for the pivo tal study , 
and will conclude when enrollment of patients in the pivotal study  closes.  
5.2 Inclusion Criteria
5.2.1 Inclusion Criteria for the Pivotal Study
Patients must meet all of the following criteria to be considered eligible for randomization in the 
pivotal study : 
1.The patient is male and is ≥3 and <18 years of age at the time of informed consent.
Note that patients who are younger than 3 years of age may be enrolled in a separate 
substudy provided that they have a documented complex rearrangement genotype of the 
iduronate -2-sulfatase gene an d meet other inclusion criteria, provided below.
2.The patient must have a documented diagnosis of MPS II.  Of the three criteria below, the 
combinations (1a AND 1b) or (1a AND 1c) will be accepted as diagnostic of MPS II:
a.The patient has a deficiency  in id
uronate -2-sulfatase e nzyme activit y of ≤10% of the 
lower limit of the normal range as measured in plasma, fibroblasts, or leukocy tes (based 
on the reference laboratory ’s normal range).
AND
b.The patient has a documented mutation in the iduronate -
2-sulfatase gene that leaves the 
FMR1 and FMR2 genes intact.  In the case of a positive family  history , the genot ype of a 
brother or uncle (with appropriate informed consent, or assent if applicable) may  be 
accepted as documentation at the discretion of the Medical Monitor.
OR
c.The patient has a normal enzy me activity  level of one other sulfatase as measured in 
plasma, fibroblasts, or leukocy tes (based on the normal range of measuring laboratory ).Page 35
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 363.The patient has evidence at Screening of Hunter s yndrome -related cognitive impairment, 
defined as follows :  
Note that separate inclusion criteria with respect to patient cognitive status at Screening 
apply to patients ≥3 and <13 years of age andto patients ≥13 and <18 years of age.
A patient who is ≥3 and <13 years of age must have one of the following criteria (3a OR
3b):
a.A GCA score ≥55 and ≤85
OR
b. If the patient has a GCA score at Screening >85, there must be evidence of a decrease in 
GCA score of ≥10 points over 12 months from a previously  documented test result in 
observational study  HGT -HIT-090.  
A patient who is ≥13 and <18 years of age must have both of the following criteria (3c AND 
3d):
c.A GCA score of ≥55 and ≤85  
AND
d.There must be evidence of a decrease in GCA score of ≥10 points over 12 months from a 
previously  documented test resul t in observational study  HGT -HIT-090.  
4.The patient has received and tolerated a minimum of 3 months of therapy  with Elaprase 
during the period immediately  prior to Screening.
5.The patient must have sufficient auditory capacity, with or without hearing aids in the 
Investigator ’s judgment, to complete the required protocol testing, and be compliant with 
wearing the aid on scheduled testing day s.
6.The patient’s parent(s) or legally  authorized guardian(s) must have voluntarily  signed an 
Institutional Review Boa rd/Independent Ethics Committee approved informed consent form 
after all relevant aspects of the study  have been explained and discussed.  Consent of the 
patient’s parent(s) or legally  authorized guardian(s) and the patient’s assent, if applicable, 
must be obtained prior to the start of an y stud y procedures.
Patients must meet all of the following criteria to be considered eligible for enrollment in the 
separate substudy : 
1.The patient is male and is <3 years of age at the time of informed consent.
2.The pati ent must have a documented diagnosis of MPS II.  T he following two ty pes of 
documentation will be accepted as diagnostic of MPS II:
a.The patient has a deficiency  in iduronate -2-sulfatase enzy me activit y of ≤10% of the 
lower limit of the normal range as meas ured in plasma, fibroblasts, or leukocy tes (based 
on the reference laboratory ’s normal range)
AND
b.
The patient has a documented complex chromosomal rearrangement of the 
iduronate -2-sulfatase gene that leaves the FMR1 and FMR2 genes intact Page 36
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 37In the case of a positive family  history , the genot ype of a brother or uncle (with 
appropriate informed consent, or assent if applicable) may  be accepted as documentation 
at the discretion of the Medical Monitor.
3.The patient has received and tolerated a minimum of 3 months of therap y with Elaprase 
during the period immediately  prior to Screening.
4.The patient must have sufficient auditory capacity, with or without hearing aids in the 
Investigator ’s judgment, to complete the required protocol testing, and be compliant with 
wearing the aid on scheduled testing day s.
5.The patient’s parent(s) or legally  authorized guardian(s) must have voluntarily  signed an 
Institutional Review Board/I ndependent Ethics Committee approved informed consent form 
after all relevant aspects of the stud y have been explained and discussed.  Consent of the 
patient’s parent(s) or legally  authorized guardian(s) must be obtained prior to the start of an y 
study  procedures .
5.3 Exclusion Criteria
Patients who meet an y of the following criteria are not eligible to be randomized into the pivotal 
study  or enrolled in the separate substudy : 
1.The patient has clinicall y significant non -Hunter sy ndrome -related CNS involvement (such 
as Fragile -X syndrome) which is judged b y the Investigator to be likely  to interfere with t he 
accurate administration and interpretation of protocol assessments.
2.The patient has a large chromosomal deletion or complex rearrangement genoty pe that 
includes an inactivation and/or deletion of the FMR1 and/or FMR2 genes. 
3.The patient has a significan t medical or ps ychiatric comorbidity (ies) that might affect study  
data or confound the integrit y of stud y results.
4.The patient has contra -indications for performance of lumbar puncture such as 
musculoskeletal /spinal abnormalities or risk of abnormal bleedi ng. 
5.The patient has a history  of complications from previous lumbar punctures or technical 
challenges in conducting lumbar punctures such that the potential risks would exceed 
possible benefits for the patient. 
6.The patient has an opening CSF pressure upo n lumbar puncture that exceeds 30 cm H 2O.
7.The patient has experienced infusion -related anaphy lactoid event(s) or has evidence of 
consistent severe adverse events related to treatment with Elaprase which, in the 
Investigator’s opinion, may  pose an unnecessa ry risk to the patient.
8.The patient has received a cord blood or bone marrow transplant at an y time or has received 
blood product transfusions within 90 day s prior to Screening.
9.The patient has a history  of poorly  controlled seizure disorder.
10.The patient i s unable to comply  with the protocol (eg, has significant hearing or vision 
impairment, a clinicall y relevant medical condition making implementation of the protocol 
difficult, unstable social situation, known clinically  significant ps ychiatric/behavioral 
instability , is unable to return for safety  evaluations, or is otherwise unlikely  to complete the 
study ), as determined b y the Investigator .
11.The patient is enrolled in another clinical stud y that involves clinical investigation or use of 
any investigationa l product ( drug or [intrathecal/spinal device] device ) within 30 day s prior 
to study  enrollment or at any  time during the study.Page 37
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 3812.The patient has an y known or suspected h ypersensitivity  to anesthesia or is thought to be at 
an unacceptabl y high risk for anes thesia due to compromised airway s or other conditions.
13. The patient has a condition that is contraindicated as described in the SOPH-A- PORT Mini 
S IDDD Instructions for Use , including:
a.The patient has had, or may  have, an allergic reaction to the materials of construction of 
the SOPH -
A-PORT Mini S device
b.The patient’s bod y size is too small to support the size of the SOPH -A-PORT Mini S 
Access Port, as judged by the Investigator
c.The patient’s drug therapy requires substances known to be incompatible with the
materials of construction 
d. The patient has a known or suspected local or general infection
e.The patient is at risk of abnormal bleeding due to a medical condition or therap y
f.The patient has one or more spinal abnormalities that could complicate safe implan tation 
or fixation
g.The patient has a functioning CSF shunt device
h.The patient has shown an intolerance to an implanted devicePage 38
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 396STUDY TREATMENT
6.1 Description of Treatments
6.1.1 Investigational Product
The investigational product to be used in this study  is idursul fase-IT10 mg for intrathecal use.
The idursulfase -IT drug product is an isotonic ,sterile solution intended for IT administration.  I t 
is formulated as a 10 mg/mL  protein concentration in 154 mM NaCl, pH 6.0, 0.005% 
polysorbate 20.  It does not contain an y preservatives and is intended for single use.
The active ingredient of the idursulfase -IT drug product is idursulfase (recombinant human 
iduronate -2-sulfatase ) the same active ingredient in the commerciall y available drug Elaprase.  
However, Elaprase and idursulfase -IT are specifically  formulated for the IV and IT 
compartments respectively ; they  cannot be interchanged.  
In contrast to Elaprase, idursulfase- IT is speciall y formulated for, and compatible with, direct 
introduction into the IT space, because it is isotonic and contains excipients suitable for IT 
administration.   
6.1.2 Intrathecal Drug Delivery Device
The investigational product will be ad ministered via the SOPH -
A-PORT Mini S I mplantable 
Access Port.  The SOPH -A-PORT Mini S is intended for long -term, intermittent access to the IT
space for delivery  of investigational product . The device is CE marked in the EU.
The SOPH -A-PORT Mini S device comprises the following seven components:
One SOPH -A-PORT Mini S Access Port
One intrathecal port closed- tip catheter
One guidewire
Two suture wings
One 14 -gauge Tuoh y needle
One 22 -gauge non- coring Huber needle
One Luer lock Connector.
Further details are provided in the Instructions for Use.
6.1.3 Comparator
The comparator group receives no study treatment.Page 39
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 406.2 Treatment sAdministered
After informed consent is signed, all patients who meet the eligibility  requirements for the 
pivotal study  will be ra ndomized on a (2:1) allocation to one of the following pivotal study  arms:
IT Treatment Arm: treatment with idursulfase -IT 10 mg administered intrathecall y 
via the surgicall y implanted IDDD (or lumbar puncture) once every  28 days
No IT Treatment Arm : no study  treatment 
All patients 
will continue to receive standard -of-care therap ywith Elaprase during the stud y.  
Elaprase wil l not be provided by  the Sponsor , but rather will be prescribed by  the patient’s 
physician in accordance with local prescribing information.
Patients who are randomized to rec eive treatment with idursulfase -IT will be scheduled to 
undergo surgical placemen t of the SOPH -
A-PORT Mini S device .  At least 14 day s will be 
allowed for recovery  following the placement of the IDDD before the administration of the first 
intrathecal idursulfase -IT dose.  During this time, the patient will receive standard perioperativ e 
care.  Thereafter, these patients will be administered idursulfase -IT 10 mg as an IT injection once 
monthly  for 12 months.  
Patients who are randomized to no treatment will not undergo surgical placement of an IDDD
and will not be administered idursulfa se-IT during the study .  
The separate substud y is an open -label, single arm study .  Patients who are enrolled in the 
separate substudy  will undergo surgical placement of the SOPH -A-PORT Mini S device and 
receive treatment with idursulfase -IT 10 mg administered intrathecally  via IDDD (or lumbar 
puncture) once every  28 day s for 12 months in addition to standard -of-care Elaprase therap y.
6.3 Selection and Timing of Dose for Each Patient
The dos ingschedule for the study is described above in Section 6.2.
Those patients randomized to treatment in the pivotal study  will undergo surgical implantation of 
the IDDD .  Treated patients will then receive 12 monthly  IT injections of idursulfase -IT 10 mg ,
once every  28 day s.
Patie nts who are enrolled in the separate substudy  will undergo surgical implantation of the 
IDDD.  P
atients in the substudy  will receive the same treatment regimen as 
idursulfase -IT-treated patients in the pivotal study .  
Note that ,
onIT Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a 
minimum of 48 hours after IT administration of idursulfase- IT.
6.4 Method of Assigning Patients to Treatment Groups
The pivotal trial is randomized and open label. Patients who have met the inclusion and 
exclusion criteria will be randomized (open -label, assessor -blinded) in a 2:1 randomization Page 40
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 41scheme to either IT treatment or no IT treatment. The randomization will be stratified according 
to baseline (Screening Visit) GCA score ( ≤70 or >70) .  The randomiza tion schedule will be 
generated and administered by  a third -party  (eg, IVR vendor) independent of the project team.
In a separate substud y, additional patients may be enrolled who have a complex rearrangement 
genot ype in the iduronate -2 sulfatase gene and who are below the age of 3 y ears at the time of 
informed consent.  Such patients are ineligible for the pivotal study  and will not be randomized, 
but will receive idursulfase -IT treatment.  The separate substud y is an open -label, single arm 
study .  Data fr om patients participating in this separate substudy  will be analy zed separately .
6.5 Blinding
Single and double blinding of patients, their families, and the Principal Investigator is not 
possible due to the absence of a sham device, sham injections, or placeb o. 
The Sponsor will 
work with each site to clarify  the process for assessor blinding. 
Every effort will be made to blind the assessors of the primary  and secondary  endpoints obtained 
from the DAS -II and VABS -II.  The assessors responsible for these eval uations will not be 
informed of patients’ randomization assignments.  The families will be instructed not to share 
this information with the assessors.  
Different assessors will be responsible for administration of the DAS -II and VABS -II.  The 
DAS -II will be administered by  a qualified psy chologist.
6.6 Infusion R
eactions and Management
Infusions of proteins can be associated with reactions to the infusion that may  or may  not be 
immune mediated .  Thus, potential reactions to the infusion of an investigational product are 
unpredictable .  
Infusion-related reactions have been observed in patients receiving IV enzyme replacement 
therap y with Elaprase, with sy mptoms including cutaneous reactions (rash, pruritus, and 
urticaria), p yrexia, headache, h ypertension, and flushing.  Previous experience with Elaprase is 
fully  described in the Elaprase US Package Insert and the European Union (EU) Summary  of 
Product Characteristics (SmPC).  Pretreatment with antihistamines and/or corticosteroids may 
prevent subsequent reactio ns in those cases where sy mptomatic treatment was required. The 
safet y information reported from administration of Elaprase may  be relevan t to management of 
adverse events in relation to idursulfase -IT.
Successful management of Elapras e infusion-related a dverse events included slowing or 
interrupting the infusion at the time of the event or pre -treatment with low -dose corticosteroids 
and/or antihistamines.  M ost adverse events of this ty pe were treated with antihistamines such as 
chlorpheniramine (IV admin istration preferred if available), ox ygen, or mild glucocorticoids 
such as h ydrocortisone and prednisolone.  All were monitored closel y until symptoms of the 
reactions had subsided.  In clinical trials of Elaprase , anapparent decrease in the overall rates of 
adverse events, and specifically  infusion -related adverse events, was observed over time, 
suggesting that patients may  better tolerate infusions during long -term therapy . Page 41
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 42Because idursulfase -ITis administered intrathecally, it is not expected that sy stemic blood levels 
will be high enough to cause an infusion- related reaction.  Clinical studies with 
idursulfase -IT-have not revealed adverse events consistent with infusion -related reactions 
sometimes observed with IV Elaprase infusion .  There have been no significant concerns 
regarding infusion -related immune reactions following IT administration in studies 
HGT -HIT-045 and HGT -HIT-046.
Note that an y patient with prior experience of infusion -related anaph ylactoid event(s) or 
evidence of consistent severe adverse events related to treatment with Elaprase is excluded from 
participating in thisstudy .
6.7 Restrictions
6.7.1 Prior Therapy
All patients are to have received and tolerated 3 months of therapy  with idursulfase IV (Elaprase) 
therap y prior to participation in this study .
Prior therapies that areexclusion criteria for the study  are: prior treatment with an investigational 
product ( drug or [intrathecal/spinal] device )within the 30 day s prior to study  enrollme nt or 
anytime during the study ; receipt of a cord bl
ood or bone marrow transplant at any  time ;and
receipt of blood product transfusions within 90 days prior to Screening.
6.7.2 Fluid and Food Intake 
Not applicable.
6.7.3 Patient Activity Restrictions
Please refer to the SOPH -A-PORT Mini S I nstructions for Use for details regarding patient 
activity  restrictions for patients to be implanted with this device.
6.8 Treatment Compliance
Treatment with the investigational product will be administered via an IDDD under the 
supervision of the investigator and in the controlled env ironment of a clinical center ; therefore, 
full 
patient compliance with treatment is anticipated in this study .
The initial implantation and revision and/or explantation of the SOPH -A-PORT Mini S will be 
performed b y pediatric or general neurosurgeons or anesthesiologists who have experience in 
port and catheter implant procedures and intrathecal access procedures.  Please refer to the 
Instructions for Use for further details.
Investigational product administration will be performed in a clinical setting b y appropriatel y 
trained and skilled healthcare providers (nurses or phy sicians) with knowledge of the patient’s 
drug regimen and experienced in accessing vascular or central nervous sy stem (CNS) ports or 
CNS infusion pumps.  Patients and patients’ families will not be directl y using the device to Page 42
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 43administer drugs and will have limited direct interaction with the device as there is minimal care 
required both during the immediate postoperative period as the implant site heals, and at times of 
drug administration.
6.9 Packaging and Labeling
All packaging and labeling will be in accordance with applicable regulatory  requirements.
6.9.1 Investigational Product
Idursulfase -IT drug product is a sterile liquid formulation for IT administration that is packaged 
in 2-cc Type I borosilicate glass vials.  The drug product is filled todeliver a minimum dose 
volume of 1 mL per vial with minimal waste and for handling convenience in the clinical setting.
6.9.2 I ntrathecal Drug Delivery Devi ce
The SOPH -A-PORT Mini S Access Port is available in one size, individually packaged, with 
other SOPH-A- PORT Mini S components in double peel- off, sterile, py rogen -free packaging, 
sterilized with Ethy lene Oxide.  I nstructions for use are also included in the packaging. A 
guidewire is provided in separate double pouch, sterile, py rogen -free packaging.
Labels are provided on the outer carton and on both the SOPH -A-PORT Mini S box and 
guidewire/cannula package inside .
6.9.3 Storage and Accountability
6.9.4 Investigational Product 
Idursulfase -IT will be shipped by  Shire HGT or a qualified distributor to the clinical study  site(s) 
at 5±3 °C (36 to 46 °F).  The investigational product should be handled as follows:
idursulfase -IT vials should be stored at 5±3ºC (36 to 46°F). 
idursulfase -IT is intended for IT use onl y.
It isrecommended that idursulfase -IT be filtered prior to use through a standard 0.2 
µm filter.
Perform a visual inspection of each vial. Idursulfase -IT is a clear to slightly  
opalescent, colorless solution.  Do not use if the solution in the vials is discolo red or 
particulate matter is present.
DO NOT SHAKE. Idursulfase -IT should not be agitated vigorousl y at an y time.  
Withdraw the volume of idursulfase -IT from the vial .
Do not mix with, or administer in conjunction with other drug solutions.
idursulfase -IT must be used as soon as possible after it is prepared, because it does 
not contain preservatives.  
Idursulfase -IT is supplied in single -use vials.  Only  1 dose of idursulfase -IT is to be 
withdrawn from a vial. Page 43
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 44The disposition of all investigational pr oduct delivered to a Principal Investigator must be 
recorded on a patient -by-patient basis by  completing the Accountabilit y Log.  The date and time 
of administration of the investigational product and use of the device must be documented on the 
patient’s a ppropriate eCRF.
The Principal Investigator, Clinical Research Coordinator, or designee (eg, Pharmacist) must 
ensure that all documentation regarding investigational product receipt, storage, dispensing, 
loss/damaged and return of used/unused product is co mplete, accurate, and read y for review at 
each monitoring visit and/or audit.  The sites must ensure that the investigational product is 
available for the monitor to inventory  and prepare for return shipment to the Sponsor or 
designee, if required.
See the Pharmacy  Manual for additional details.
6.9.5 Intrathecal Drug Delivery Device
The disposition of all SOPH -A-PORT Mini S devices delivered to a Principal I nvestigator must 
be recorded on a patient- by-patient basis by  completing the Accountability  Log.  The date and 
time of administration of the investigational product and use of the SOPH -A-PORT Mini S 
device must be documented on the patient’s appropriate eCRF.
The Principal Investigator, Clinical Research Coordinator, or designee (eg, Pharmacist) must 
ensure that all documentation regarding receipt, storage, dispensing, loss/damaged 
SOPH -A-PORT Mini S devices and return of used/unused SOPH -A-PORT Mini S device(s) is 
complete, accurate, and read y for review at each monitoring visit and/or audit.  The sites must 
ensure that the SOPH -A-PORT Mini S devices are available for the monitor to inventory and 
prepare for return shipment to the Sponsor or designee, if required.
The SOPH -A-PORT Mini S and its components are sterile, single- use devices.
Please refer to the IDD D Manual for device return instructions.
6.9.6 Comparator Product 
Not applicable to this study .Page 44
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 457STUDY PROCEDURES
The pivotal study  will consist of a Screening period of up to 28 day s prior to randomization 
(during which re-testing of patients who were initiall y unwilling or unable to comply with all 
scheduled screening assessments is permitted).  
Those patients randomized to the IT treatment arm will undergo surgical implantation of the 
SOPH -A-PORT Mini S IDDD followed b y a post -operative recovery  period of at least 14 day s 
prior to the first IT administration of idursulfase -IT.  Treated patients will then receive 12 
monthly  IT injections of idursulfase -IT corresponding to a treatment and assessment interval of 
13 (28- day) months from randomization to the end -of-study  (EOS) evaluations.  L ikewise, 
patients randomized to the no IT treatment arm will be assessed over 13 (28-day) months after 
randomization.
Patients in the IT treatment arm of the pivotal study will be assessed according to the following 
schedule: 
Screening (Weeks -1 to -4 [Day  -28 to Day  -1])
Randomization (Week 0 [Day  0])
Pre-surgery , Surgery ,and Post -operative Recovery (Weeks 2 and 3)
Treatment and Assessments(Week 4 through Week 48 [±7 day s])
End of study  (EOS, Week 52 [±7 day s])
Follow -up (tel ephone contact) 7 (±2) days from the Week 52 (or EOS)
Patients in the no IT treatment arm of the pivotal study  will be assessed according to the 
following schedule: 
Screening (Weeks -1 to -4 [Day  -28 to Day  -1])
Randomization (Week 0 [Day  0])
Assessments (Week 4 through Week 48 [±7 day s])
End of study  (EOS, Week 52 [±7 day s])
Follow -up (telephone contact) 7 (±2) day s from the Week 52 (or EOS) 
The separate substud y is open label and single arm.  Patients who meet all entry  criteria for 
participation in t he substudy  will be considered enrolled on Day  0.  Thereafter, patients who are 
enrolled in the separate substudy  will follow the same schedule of study  visits as 
idursulfase -IT-treated patients in the pivotal study .  
Patients in the substudy  will be asse ssed according to the following schedule: Page 45
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 46Screening (Weeks -1 to -4 [Day  -28 to Day  -1])
Enrollment (Week 0 [Day 0])
Pre-surgery , Surgery ,and Post -operative Recovery (Weeks 2 and 3)
Treatments and assessments (Week 4 through Week 48 [±7 day s])
End of stu
dy (EOS, Week 52 [±7 day s])
Follow -up (telephone contact) 7 (±2) day s from the Week 52 (or EOS) 
Patients in both the IT treatment and no IT treatment arms of the study  will complete EOS 
assessments at Week 52 (Visit Month 13).  All patients will particip ate in a follow -up contact (b y 
telephone) approximately  7 day s after the EOS visit.
A patient who discontinues or is withdrawn prior to study  completion will be asked to participate 
in an EOS visit within approximately  30 day s after withdrawal or discontinuation (EOS 
assessments for such patients will be the same as Week 52 assessments), and also to complete a 
follow up contact approximately  7 day s after the patient’s EOS visit.  There is no replacement of 
patients who do not complete the study .
All patient s will receive weekl y IV Elaprase infusions as prescribed throughout the study .  Note 
that,on IT Dosing Weeks, 
the IV infusion of Elaprase should be scheduled to occur a minimum 
of 48 hours after IT administration of idursulfase -IT.
See Section 13 for the Schedule of Events for the pivotal study  (Appendix 1 and Appendix 2 ) 
and separate substud y (Appendix 3).
All data collected are to be recorded on the appropriate electronic case report form ( eCRF ).
Details for stud y procedures including sample collection are described in the Operations Manual.
7.1 Informed Consent
Prior to conducting any study -related procedures, written informed consent (signed and dated) 
must be obtained from the patient’s parent(s) or legall y authorized representative(s) (and assent 
from the patient , if applicable).   The nature, scope, and possible consequences, in cluding risks 
and benefits, of the stud y will be explained by the Investigator or designee in accordance with 
the guidelines described in Section 11.4.  Documentation and filing of informed consent 
documents sho uld be completed according to Section 11.4.
7.2 Study Entrance Criteria
Each patient will be reviewed for eligibility  against the study  entrance criteria .  Patients who do 
not meet the study  entrance criteria will not be allowed to participate in the study .  The reason(s) 
for the patient’s ineligibility  for the stud y will be documented.   No protocol exemptions will be 
permitted.   Page 46
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 477.3 Medical History
A standard medical history  of each patient will be obtained at Screening and will include age at 
onset of Hunter s yndrome symptoms, age of Hunter s yndrome diagnosis, evidence of 
iduronate -2-sulfatase deficiency , genot ype, family history of Hunter s yndrome, Hunter s yndrome 
signs and s ymptoms in the following domains:  head/nec k, ey es, mouth, ear, nose, throat, 
chest/lung, cardiovascular sy stem, abdomen, gastrointestinal sy stem, genitourinary  system, skin, 
skeletal sy stem, neurological sy stem, ps ychiatric disorders and surgical history .
Patients who do not have a documented diag nosis of Hunter s yndrome in their medical history 
will provide a blood sample at Screening to assay  for iduronate -2-sulfatase enzy me activity  in 
plasma, fibroblasts, or leukocy tes (patients must exhibit 
≤10% of the reference laboratory ’s 
lower limit of the normal range to confirm diagnosis).  These samples will also be assay ed for 
normal enzy me activity  level of one other sulfatase in plasma, fibroblasts, or leukocy tes (based 
on the reference laboratory ’s normal range).
A blood sample for genotyping is to be collected during Screening to document the diagnosis of 
Hunter s yndrome .  Anal ysis of iduronate -2-sulfatase genoty pe will be required for all patients 
who have not had a previous genot
yping performed at Greenwood Genetic Center’s Diagnostic 
Laboratory  (Greenwood, South Carolina, USA).   Even patients for whom prior genot yping was 
performed at Greenwood Genetic Center’s Diagnostic L aboratory  may  need have a repeat 
analysis performed if the original information was insufficient for an unambiguous classifica tion 
of genoty pe (eg, to document the integrit y of the FMR1 and FMR2 genes in patients with 
complex mutations/chromosomal rearrangements).
7.4 Echocardiogram
An echocardiogram will be performed as part of the study  eligibility  criteria.   This procedure will 
not be necessary  if the patient has had an echocardiogram performed within 3 months of study  
entry ,the data are available ,and deemed satisfactory  for evaluation of anesthesia risk .
7.5 Device Related Procedures
7.5.1 IDDD Implantation and Revision
The IDDD will be s
urgically  implanted or revised at the clinical site. Procedures for 
implantation and revision are detailed in the device’s Instructions for Use . Standard hospital 
procedures for surgery  will be followed; the patient will be under general anesthesia for t his 
procedure.
An additional medical device, the catheter passer, is necessary  for the implantation procedure.  
The catheter passer is a sterile, single use device that will be used in the subcutaneous placement 
of the catheter. The Phoenix Neuro Disposab le Catheter Passer, manufactured b y Sophysa is CE 
marked in the EU and cleared under K853370 in the US.
Details of the implantation/revision and malfunctions/failure will be documented on the patient’s 
eCRF.Page 47
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 487.5.2 X- ray Verification of Intrathecal Drug Delivery Device Placement
A postoperative x -ray check of the IDDD will be performed following surgery  to verify  proper 
installation and confirmation of I DDD placement at the mid- thoracic level. The x -rays may  be 
performed to check placement of the device, as need ed, throughout the study , and will be 
performed at the end of the study  (to verify  that the IDDD is in the correct position). At a 
minimum, the date of the x- ray verify ing correct IDDD placement will be documented on the 
patient’s eCRF. If the device req uires revision or replacement during the study , additional x- rays 
will be taken to document the proper positioning of the device. If the IDDD malfunctions, an 
x-ray will be performed to assess the potential cause of malfunction.
7.5.3 CSF Sampling Procedure
Cerebrospinal fluid will be sampled via the device. If this is not possible, and if CSF sampling is 
necessary , either for adherence to the protocol, or to investigate clinical concerns, a lumbar 
puncture may  be performed to sample CSF, either with or without administration of drug 
afterwards (See Section 4.1.1 ).  
7.5.4 Device Removal
If at the time of a scheduled dosing it is not possible to administer a full medication dosage as 
per the standard administration steps de tailed in the device’s I nstructions for Use due to a device 
related issue, the IDDD will be declared a device malfunction. If the device malfunction is 
irreversible and cannot be corrected without a device surgical intervention, the IDDD will be 
declared a device failure, starting from the date of the initial malfunction. 
The IDDD will then be surgically  removed or revised and a new device and/or device 
components will be re -implanted at the earliest possible opportunity , preferabl y at the same time. 
Details of the device removal will be recorded in the patient’s eCRF. For further details, please 
refer to the SOPH -A-PORT Mini S Instructions for Use .
Patients will have the IDDD removed when they discontinue from the study , unless the patient is 
continuing to receive treatment through another mechanism (eg, extension study , expanded 
access program ).
7.6 Investigational Product Administration
Idursulfase -IT will be administered every 28 day s by means of the IDDD.  A visual examination 
of both the port and cathet er track will be performed before each IT injection.
A 22 -gauge Huber non -coring needle is to be used for access to the implanted port; standard 
hypodermic needles would damage the septum and may  cause leakage. If no needle free 
connector is present, eith er a stopcock of the Huber needle infusion set’s clamp is to be used to 
prevent CSR backflow and to mitigate the risk of air entering the s ystem. It is possible to use 
other brands of Huber non -coring needles, provided that their specifications are identi cal to that 
of the Huber needle (22G) supplied by  Sophy sa in a SOPH -A-PORT Mini S.Page 48
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 49If the intrathecal space is not accessible via the IDDD, idursulfase -ITmay be administered by  
lumbar puncture (See Section 4.1.1 ).  
The injection date, injection start/stop time, planned dose, injection volume, and flush volume 
will be recorded on the patient’s eCRF.  
Intrathecal administration of investigational product will be preceded b y CSF sampling for safet y 
laboratory  analysis (cell count, protein, glucose), pharmacod ynamic analysis (GAG 
concentration), and anal yses of idursulfase enzy meand anti-idursulfase antibod ies.  The total 
volume of investigational product and flush administered is targeted towards replenishing the
volume of CSF withdrawn.  Therefore, while the total volume of idursulfase -IT administered 
will be less than the total volume of CSF withdrawn, additional saline will be administered to 
ensure a balance between the amount administered and the amount withd rawn.
Specificall y, the investigational product will be administered in a volume of 1 mL  (1 mL  of a 
10mg/mL  solution) (See Section 
6.1.1).  The minimal proposed flush volume is 2 mL , so the 
minimal volume admin istered will be 3 mL.  Additional volume of preservative -free saline will 
be administered to add up to a total volume that is equal to that which was withdrawn.
This design was intended to mitigate an y risk of overfilling or underfilling the ITcompartment
as well as the risk of inducing acute intracranial hypertension or brain herniation.
Patients will remain under observation in the hospital setting (may  include lounge, infusion 
center, or waiting room) for at least 4 hours post administration of investig ational product and 
will be discharged when deemed clinicall y stable by the Investigator.  The patient will need to be 
examined the following day by the Investigator ; however, there is no requirement for an
overnight hospital stay .If a decision is made t o keep the patient overnight for convenience, this 
should not initiate a serious adverse event report. 
7.7 Pharmacokinetic Assessments
Blood samples will be collected for measurement of serum concentrations of idursulfase and 
determination pharmacokinetic par ameters after intrathecal administration. CSF samples will 
also be collected immediately  prior to IT dosing for measurement of CSF concentrations of 
idursulfase. The r esults of these assessments will be addressed in a separate pharmacokinetic 
report.
The blood and CSF sampling for pharmacokinetic assessments is provided in the Schedule of 
Events for patients in the treated arm of the pivotal study  (Append ix 1) and in the separate 
substudy  (Appendix 3).
7.8 Pharmacodynamic Assessments
Cerebrospinal fluid and urine samples will be collected for measurement of the concentration of 
GAG. Page 49
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 507.9 Efficacy Assessments
The efficacy  endpoints are specified in Section 3. 
7.9.1 Neurodevelopmental 
Assessment Tools
The study  methodology  will include standardized neurodevelopmental assessments to provide a 
quantifiable measure of patient neurodevelopmental status .6  Neurodevelopmental status w ill be 
assessed over time by  measuring cognitive and adaptive functions as follows
.
Cognition: t he Differential Ability  Scales, Second Edition (DAS- II)16will be used to assess all 
randomized patients.  For patients participating in the separate substud y only (ie, patients with a 
complex rearrangement genoty pe of the iduronate -2-sulfatase gene and who are below the age of 
3 years) cognition will be assessed initially  using the Bay ley Scales of 
Infant Development, 
Third Edition (BSID -III).19  When these patients reach at least 42 months of age, if considered 
evaluable using the DAS -II instrument, they  will transition to use of the DAS -II for continued 
assessment of cognition.
Adaptive Behaviors: the Vineland Adaptive Behavioral Scales, Second Edition (VABS -II)18will 
be used to assess all patients.
It is intended that full neurodevelopmental assessments be conducted for all patients; however, it 
is recognized that the feasibility  of conducting these assessments may  be dependent on the 
patient’s ability  to cooperate and/or level of cognitive impairment.  
7.10 Health Status Assessment
The health status of patients will be assessed using the EQ -5D questionnaire, a standardized 
instrument for use as a measure of health status which is applicable to a wide range of hea lth 
conditions and treatments.20, 21  The EQ -5D provides a descriptive profile and index value for 
health status
.
7.11 Safety Assessments
Safety  will be assessed by  adverse events (adverse events, by  type, severity, and relationship to 
treatment [idursulfase -IT,the IDDD, device surgical procedure, or IT administration process] 
and IV Elaprase infusion ), changes in clinical laboratory  testing (serum chemistry , hematology , 
urinaly sis), phy sical and neurological examination , vital signs, 12- lead ECG , CSF chemistries 
(including cell counts, protein, and glucose), anti
-idursulfase antibodies in CSF and serum, and 
determination of antibodies having enzy me neutralizing activity .
SOPH -A-PORT Mini S assessments will include measur es of device implantation, device 
function, device longevity, record of revisions, removals, and replacements of the implanted 
IDDD, and adverse events associated with the device.  This data will be collected on the patient’s 
electronic case report form (e CRF) from the time of implantation and continue throughout the 
study  as long as the SOPH -A-PORT Mini S remains implanted.Page 50
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 517.11.1 Physical and Neurological Examination
Aphysical examination will be performed with a thorough review of body  systems on specified 
study days. 
Physical examinations will include a review of the patient’s general appearance, neurological 
examination, as well as evaluation of the body  systems listed in Table 7- 1and the device port 
and catheter t rack.  An y abnormal change in findings will be recorded as an adverse event on the 
appropriate eCRF .
Table 7-1 Assessments for Physical Examinations
Assessment Assessment
General appearance Endocrine
Head and neck Cardiovascular
Eyes Abdomen
Ears Genitourinary
Nose Skin
Throat Musculoskeletal
Chest and lungs Neurological
Port and catheter track
7.11.2 Height and Weight 
Height ( cm) and weight ( kg) will be recorded for all patients at Screening and during the study  at 
time points specified in the Schedule of Events.  The clinical site staff will be instructed to use a 
calibrated scale for weight measurement.  
7.11.3 Head Circumference
Head circumference (cm) will be measured in a uniform manner for all patients.  
7.11.4 Hearing Assessment
Hearing assessments will be performed using age -appropriate testing methods based on the 
patient’s age at the time of testing.  It is recognized that the ability  to conduct this assessment 
will depend on the patient’s ability  to coope rateand that it might not be possible to complete a 
hearing assessment for every  patient.  A reasonable effort should be made to perform a hearing 
assessment for each patient; however, inability  to collect these data may  not be considered a 
protocol devia tion.  
7.11.5 Vital Signs
Vital signs are to be recorded for all patients and will include pulse, blood pressure, respiration 
rate, and temperature .Page 51
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 527.11.6 Electrocardiogra m
An electrocardiogram (12- lead) will be performed in accordance with the clinical site’s standar d 
practice(s) .  Electrocardiogram recordings will be read locally  at the clinical site by  a qualified 
cardiologist .  The ECG will include assessment of heart rate, sinus rh ythm, atrial or ventricular 
hypertrophy , and assessment of PR, QRS, QT, and correcte d QT (QTc) intervals.  Identification 
of an y clinicall y significant findings and/or conduction abnormalities will be recorded on the 
eCRF .  
7.11.7 Intracranial Pressure Measurement
Intracranial pressure (I CP) measurement (cm of H 2O) will be assess edfor all pat ients.  The ICP 
measurement will be conducted bylumbar puncture and while the patient is under anesthesia.  
Patients with a surgically implanted I DDD should undergo X -ray prior to lumbar puncture to 
verify  the position of the catheter.
7.11.8 Brain Magnetic Res onance Imaging
Patients will undergo magnetic resonance imaging (MRI) of the brain .  Brain structure volumes 
will be measured
.  Refer to the Study  Operations Manual for specific procedures and 
precautions.  
7.11.9 Clinical and Other Laboratory Tests
Blood and ur ine samples will be collected as described in this section for clinical laboratory  
testing .  All blood samples will be collected byvenipuncture . Patients will be in a seated or 
supine position during blood collection .
Clinical laboratory  tests will include the following (See Table 7- 2):
Table 7-2List of Laboratory Tests
Hematology:
-Hematocrit (Hct)
-Hemoglobin (Hgb)
-Mean corpuscular hemoglobin (MCH)
-Mean corpuscul ar hemoglobin 
concentration (MCHC)
-Mean corpuscular volume (MCV)
-Platelet count
-Red blood cell (RBC) count 
-White blood cell (WBC) count with 
differential 
Urinalysis: 
-Appearance (clarity and color)
-BilirubinSerum Chemistry:
-Albumin (ALB)
-Alkaline phosphatase (ALK -P)
-Alanine aminotransferase (ALT; 
SGPT)
-Aspa rtate aminotransferase (AST; 
SGOT)
-Blood urea nitrogen (BUN)
-Calcium (Ca)
-Carbon dioxide (CO 2)
-Chloride (Cl)
-Creatinine
-Creatine phospho kinase
-Gamma -glutamyl transferase (GGT)
-GlobulinPage 52
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 53Table 7-2List of Laboratory Tests
-Blood
-Glucose
-Ketones
-Leukocyte esterase
-Micr oscopic examination of sediment 
-Nitrite 
-pH
-Protein
-Specific gravity
-Urobilinogen
Coagulation: 
-Prothrombin time (PT)
- P artial thromboplastin time (PTT)-Glucose
-Lactate dehydrogenase (LDH)
-Magnesium (Mg)
-Phosphorus (P)
-Potas sium (K)
-Sodium (Na)
-Total and direct bilirubin
-Total cholesterol
-Total protein
-Total thyroxine (T4)
-Thyroid- stimulating hormone (TSH)
-Triglycerides
-Uric acid
Urine samples will be collected for determination of GAG concentration.  Urine GAG will be 
analyzed and reported by a Sponsor -designated laboratory .  Urine creatinine will be anal yzed in 
the collected samples.  Urine GAG concentration will be normalized to urine creatinine and 
reported as mg GAG/mmol creatinine.  
7.11.10 Cerebrospinal Fluid Assessments
Cere brospinal fluid samples will be collected via the IDDD or lumbar puncture and used to 
analyze standard laboratory  parameters ( cell count, protein ,glucose ), andconcentration s of GAG 
and idursulfase enzy me.  TheCSF sample swill also be anal yzed for idursu lfase -specific 
antibodies (See Section 7.11.11 ).
Cerebrospinal fluid will be obtained from patients in the treated arm of the pivotal study  and in 
thesubstudy  at Screening (b y lumbar puncture and under general anesthesia), during surgical 
implantation of the IDDD, prior to each
intrathecal injection of investigational product, and at 
the EOS visit.  Should the IDDD become clogged, undergo mechanical complications or 
otherwise not be accessible, the CSF sample ma y be obtained b y lumbar puncture up to 12 times.
Patients in the no treatment arm of the pivotal study will undergo lumbar puncture (under general 
anesthesia) to obtain CSF sample s.
7.11.11 Antibody Assessments
Blood and CSF samples will be collected and evaluated by aShire -HGT designated laboratory  
for the presence of anti -idursulfase antibodies and antibodies with enzyme neutralizing activit y.Page 53
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 547.11.12 Device Assessments
SOPH -A-PORT Mini S assessments will include measures of device implantation, device 
function, device longevity , record of revisions, removals, and replacements of the implanted 
IDDD, and adverse events associated with the device. These data will be collected on the 
patient’s eCRF from the time of implantation and continue throughout the study  as long as the 
SOPH -A-PORT Mini S remains implanted.
7.11.13 Pregnancy Testing
Not applicable.
7.12 Sample Collection, Storage, and Shipping
Details for stud y procedures ,including sample collection ,are provided in the Operations Manual 
for this study .
7.13 Concomitant Medications, Therapies /Interventions ,and Medical/Surgical 
Procedures Assessments
All medications, therapies/interventions administered to and medical/surgical procedures 
performed on patients from the time of informed consent through the follow- up contact are 
regarded as concomitant and will be documented on the eCRF . Non-permitted (per the exclusion 
criteria ) medications, therapies, or surgical interventions will lead to exclusion from the study  or 
a possible protocol violation depending on when the non-permitted even t occurs.
All patients are to receive Elaprase during the study .Elaprase will be prescribed b y the patient’s 
physician and will be administered in accordance with local prescribing information .  Elaprase 
will not be provided by  the study  Sponsor.
Concomi tant therapies such as speech therap y, ergotherap y, music therap y
,and phy sical therapy , 
will be captured at baseline and throughout the study .
7.14 Adverse Events Assessments
7.14.1 Definitions of Adverse Events and Serious Adverse Events
7.14.1.1 Adverse Event s
An adverse event is an y noxious, pathologic, or unintended change in anatomical, phy siologic, or 
metabolic function as indicated b y physical signs, sy mptoms, or laboratory  changes occurring in 
any phase of a clinical study , whether or not considered investigational pro duct-related.  This 
includes an exacerbation of a pre -existing condition .  
Adverse event s include:Page 54
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 55Worsening (change in nature, severit y, or frequency) of conditions present at the onset of 
the study
Intercurrent illnesses
Drug interactions
Events related to or possibly  related to concomitant medications
Abnormal laboratory values (this includes significant shifts from baseline  within the 
range of normal that the Investigator considers to be clinically  important)
Clinically  significant abnormalities in ph ysical examination, vital signs, and weight
Throughout the stud y, the Investigator must record all adverse events on the AE electronic case 
report form ( eCRF ), regardless of the severity  or relationship to investigational product .  The 
Investigator should treat patients with adverse events 
appropriatel y and observe them at suitable 
intervals until the events stabilize or resolve.  Adverse event s may  be discovered through 
observation or examination of the patient, questioning of the patient, complaint by  the patient, or 
by abnormal clinical laboratory  values.
In addition, adverse events 
may also include laboratory  values that become significantl y out of 
range .  In the event of an out -of-range value, the laboratory  test should be repeated until it 
returns to normal or can be explained and the patient’s safet y is not at risk.
Additional illnesses present at the time when informed consent is given are regarded as 
concomitant illnesses and will be documented on the appropriate pages of the eCRF .  Illnesses 
first occurring or detected during the study, and worsening of a concomitant illness during the 
study , are to be regarded as adverse event s and must be documented as such in the eCRF .
7.14.1.2 Elaprase Infusion -related Adverse Event s
All patients will receive concomitant IV therapy  with Elaprase throughout their participation in 
thisstudy .  Adverse events that are potentially  related to I V Elaprase infusion will be captured.  
An Elaprase -
associated infusion -related reaction will be defined as an adverse event that begins
either during or within 24hours after the start of the infusion
,and is judged as at least possibly  
related to the infusion.  Adverse events that are considered infusion-related reactions will be 
noted as such in the appropriate field on the e CRF .  The most common infusion -related adverse 
events that have been reported in patients with Hunter sy ndrome during Elaprase infusions are 
listed in Section 6.6.  Note that, during weeks of IT dose administration , the IV infusion of 
Elaprase should be scheduled to occur a minimum of 48 hours after IT dosing .
7.14.1.3 IDDD- related Adverse Events 
Examples of adverse events related to use of the IDDD include, but are not limited to, the 
following: device failure, device malfunction, incorrect connection of IDDD components, 
erosion of the portal/catheter through the skin, fibrin sheath formation around the catheter tip, 
hematoma, implant rejection, migration of the portal/catheter, occlusion of the portal/catheter, 
portal site or subc utaneous tract infection.  The device may  also need to be replaced or repaired 
as needed.  A list of adverse effects expected with use of the SOPH-A- PORT Mini S is provided 
in Appendix 4.Page 55
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 567.14.1.4 Device Surgical Procedu re-related Adverse Events
Examples of adverse events related to surgical procedures include, but are not limited to, the 
following: IDDD implant/explant, IDDD adjustment, full revision, partial revision, I DDD 
removal, and delayed re -implantation after prev ious I DDD removal, and post operative infection.
7.14.1.5 I ntrathecal Administration Process Adverse Events
Intrathecal administration process adverse events may  include those caused by anesthesia during 
drug administration and other 
drug administration issues (eg, extravasation during infusion or 
hematoma due to the Huber needle) , or complications of lumbar puncture .
7.14.1.6 Serious Adverse Event
A serious adverse event (SAE) is any  adverse event occurring at an y dose that results in any of 
the following outcomes:
Death
Islife-threatening
Requires hospitalization.  Note, however, for the purpose of this study , overnight 
hospitalizations post intrathecal administration of idursulfase -ITthat are based on 
practical or logistical considerations, rather than safety  will not be deemed serious 
adverse events (See Section 7.6).
Requires prolongation of existing hospitalization
A persistent or significant disability  or incapacity  
A congenital anomal y or birth defect
Important medical e vents that may  not result in death, be life -threatening, or require 
hospitalization may  be considered 
a serious adverse event when, based upon appropriate medical 
judgment, they  may  jeopardize the patient and may  require medical or surgical intervention to
prevent one of the outcomes listed in this definition.  A life -threatening adverse event is defined 
as an adverse event that placed the patient, in the view of the initial reporter, at immediate risk of 
death from the adverse event as it occurred (ie, 
this definition does not include an adverse event
that, had it occurred in a more severe form, might have caused death).
7.14.1.7 Unexpected Adverse Device Event
An u nexpected adverse d evice event (UADE) is any serious adverse effect on health or safety  or 
any life-threatening problem or death caused b y, or associated with, a device, if that effect, 
problem, or death was not previously  identified in nature, severity , or degree of incidence in the 
investigational plan or application (including a supplementary  plan or application), or an y other 
unanticipated serious problem associated with a device that relates to the rights, safet y, or 
welfare of patients (21CFR812.3[s] or other regulatory  requirements, as applicable).Page 56
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 577.14.2 Device -associated Definitions
7.14.2.1 Device Revision (Parti al and Full)
Partial device revision: surgical revision/replacement of one or more component(s) of the device; 
other component(s) of the original device remain implanted and are not affected (eg, port 
revision) .
Full device revision: the device is removed (explanted) in its entirety  and a completely  new 
device is implanted.
7.14.2.2 Device Malfunction
The device does not perform as intended, based on the description in the device’s Instructions for 
Use, but does not require either a partial or full device revision.
7.14.2.3 Device Failure
The device irreversibly  fails to perform as intended and requires either a partial or full device 
revision or removal.
7.14.3 Classification of Adverse Events and Serious Adverse Events
The severit y of adverse event s will be assessed b y the I nvestigator using the National Cancer 
Institute Common T oxicity Criteria (NCI CTC) grading scale (provided in the Study  Operations 
Manual) .  If an adverse event is not described in the NCI CTC, the severity should be recorded 
based on the scale inTable 7-3.  The severit y of all adverse events and serious adverse events
should be recorded on the appropriate eCRF page as mild, moderate, 
or severe.
Table 7-3Adverse Event Seve rity
Severity Definition
Mild No limitation of usual activities.
Moderate Some limitation of usual activities.
Severe Inability to carry out usual activities.
7.14.3.1 Clarification b etween Serious and Severe
The term “severe” is often used to describe the int ensity  (severit y) of a specific event (as in mild, 
moderate, or severe m yocardial infarction); the event itself, however, may  be of relatively  minor 
medical significance (such as severe headache) .  This is not the same as “serious,” which is 
based on the o utcome or action criteria usually  associated with events that pose a threat to life or 
functioning
.  Seriousness (not severit y) and causality serve as a guide for defining regulatory 
reporting obligations.Page 57
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 587.14.4 Relatedness of Adverse Events and Serious Adverse Events
The r elationship of an adverse event or serious adverse event tostudy  treatment (study  drug , the 
IDDD
, device surgical procedure, or IT administration process ) will be assessed by  the 
investigator as follows .  The r elationship to treatment will be categorized based on the 
definitions provided in Table 
7-4.
Relationship to idursulfase -IT
Relationship to the I DDD (examples of IDDD -related adverse events are listed in Section 
7.14.1.3 )
Relationship to a device surgical procedure (surgical implantation of the IDDD, partial or 
full device revision as described in Section 7.14.1.4 )
Relationship to the I T administration p rocess (examples of IT administration process-
related adverse events are listed in Section 7.14.1.5 )
Table 7-4Adverse Event Relatedness
Relationship to Treatment Definition
Not Related Unrelated to investigational product , device, device surgical 
procedure, or IT administration process.
Possibly Related A clinical event or laboratory abnormality with a reasonable 
time sequence to administration of investigational pro duct, 
device, device surgical procedure, or IT administration process ,
but which could also be explained by concurrent disease or 
other drugs or chemicals.
Probably Related A clinical event or laboratory abnormality with a reasonable 
time sequence to admi nistration of investigational product , 
device, device surgical procedure, or IT administration process 
unlikely to be attributable to concurrent disease or other drugs 
and chemicals and which follows a clinically reasonable 
response on de -challenge .  The a ssociation of the clinical event 
or laboratory abnormality must also have some biologic 
plausibility, at least on theoretical grounds.
Definitely related The event follows a reasonable temporal sequence from 
administration of the investigational product ,device, device 
surgical procedure, or IT administration process follows a 
known or suspected response pattern to the investigational 
product , is confirmed by improvement upon stopping the 
investigational product (de-challenge) ,and reappears upon 
repeated exposure (re -challenge) .  Note that this is not to be 
construed as requiring re- exposure of the patient to 
investigational product ; however, the determination of definitely 
related can only be used when recurrence of event is observed.
The r elationship of an adverse event or serious adverse event toIV Elaprase infusion will be 
assessed b y the investigator as describe din Section 7.14.1.2 .Page 58
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 597.14.5 Procedures for Recording and Reporting Adverse Events
7.14.5.1 Adverse Event Moni toring and Period of Observation
Adverse events will be monitored continuously  throughout the study .
For the purposes of this study , the period of observation extends from the time at which informed 
consent is obtained until the patient’s final evaluation of the study .  For safety  purposes, the final 
evaluation for patients who complete th is study  will be defined as the follow -up evaluation 
performed 7(±2) days after the EOS visit.
If the Investigator considers it necessary  to report an adverse event in a study  patient occurring 
after the end of the safet y observation period, he or she should contact the Sponsor to determine 
how the 
adverse event should be documented and reported.
7.14.5.2 Reporting Serious Adverse Events
Any serious adverse event , regardless of rel ationship to investigational product , device, device 
surgical procedure, IT administration process , or IV Elaprase infusion, which occurs in a patient 
after informed consent will be recorded b y the clinical site on the SAE form .  The serious 
adverse event must be completely  described on the patient’s 
eCRF , including the judgment of the 
Investigator as to the relationship of the serious adverse event to the investigational product
and/or device .  The Investigator will promptly  supply  all information identifi ed and requested b y 
the Sponsor (or contract research organization [CRO]) regarding the serious adverse event .  
The Investigator must report the 
serious adverse event to the Shire Pharmacovigilance and Risk 
Management Department AND to the Shire HGT Medical Monitor on the SAE form .  This form 
must be completed and FAXED or EMAILED within 24 hours of the Investigator’s learning of 
the event to:
Shire Pharmacovigilance and Risk Management Department:
International FAX:  (UK) OR United States FAX:  
Email:
AND
Shire HGT Medical Monitor: , MD, PhD
Email:  
FAX:   (USA)
Any follow -up information must also be completed on the SAE form and faxed or emailed to the 
same numbers or emails listed above.Page 59
PPD
PPD
PPD
PPD
PPD
PPD
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 61Medication Error –A mistake made in prescribing, dispensing, administration and/or use of the 
investigational product.
7.17 Rem oval of Patient s from the Trial or Inve stigational Product
A patient’s participation in the study  may  be discontinued a t the discretion of the Investigator .  
The following may  be justifiable reasons for the Investigator to remove a patient from the study :
The patient exhibits non- compliance wit h the study  protocol that is considered disruptive 
to study  conduct.
The patient was erroneously  included in the study .
The patient develops an exclusion criterion .
The patient suffers an intolerable adverse event .
The study is terminated by  the Sponsor .
The patient’s parent(s) or legally  authorized representative acting on behalf of the patient is free 
to withdraw consent and discontinue participation in the study  at an y time without prejudice to 
further treatment.
If the patient’s parent(s) or legally  authorized representative(s) acting on behalf of the patient
discontinues participation in the study , or the patient is discontinued by  the I nvestigator,
reasonable efforts will be made to follow the patient through the end of study  assessments. The 
reason for refusal will be documented on the eCRF .  An y adverse events experienced up to the 
point of discontinuation must be documented on the AE eCRF .  If adverse events are present 
when the patient withdraws from the study , the patient will be re -evaluated within approximately  
30 day s of withdrawal .  All ongoing serious adverse events at the time of withdrawal will be 
followed until resolution.
7.18 Other Study Procedures
7.18.1 Safety -related Study Stopping Rules
This study  will be stopped and safet y data reviewed if any patient experiences a life -threatening
serious adverse event or a death occurs, if either is considered possibl y or probably related to the 
study  treatment ( investigational product, the IDDD, device surgical procedure, or the IT 
administration process ).  Afterreview of the safety  data, the status of the study  will be one of the 
following:
Resumed unchanged
Resumed with modifications to the protocol 
Terminated
Patient safet y in this study  will be monitored by an independent DSMB until the last patient 
completes his last scheduled study  visit/assessment . The DSMB will be an external group 
overseeing 
the safet y of the study  treatment , including both the investigational product and the Page 61
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 62IDDD, and will operate according to a charter determining the scope of its activities and 
frequency  of meetings (See Section 11.8 for additional details ).
7.19 Appropriateness of Measurements
The measures of safet y to be used in the study are appropriate for an interventional study in MPS
II patients.  These include monitoring of adverse events and medication use, both standard 
parameters for the assessment of safet y, as well as measurement of ICP and imaging.
Cognitive impairment is a key  symptom of MPS II; however, clinical research in t his area has 
been broadl y lacking, instead focusing on the biological and ph ysical aspects of the disease , and 
remains an unmet medical need .  This highlights the need for a treatment that targets the 
cognitive involvement of MPS II, and an endpoint strate gy that specifically targets the cognitive 
and behavioral sy
mptoms associated with MPS II.  The neurodevelopment measures planned for 
this study  will assess cognitive and adaptive functions in children with MPS II.  These 
assessment tools (DAS -II, VABS -II)will provide a quantifiable measure of CNS 
neurodevelopment status and are appropriate for use in the target population.
The DAS -II has been found to be valid and reliable.  Evidence from published studies and 
previous Shire HGT clinical trials demonstrat es that the DAS -II is able to detect both changes in 
a child’s ability  and stabilization of functioning over time following treatment.  
The rating of the child by the parent format of the VABS -II is consistent with the FDA Patient -
reported Outcome (PRO) G
uidance, which states that caregiver reports must be based on 
observable behaviors only .  
The concepts measured by  the DAS -II were mapped onto an MPS II conceptual model.  The 
concept mapping exercise indicated adequate concept coverage across the three assessment tools, 
collectively .  Following feedback from experts in the field of neurodevelopmental functioning, 
the concept mapping exercise was repeated for the VABS- II.  The VABS -II was found to have 
strong concept coverage when combined with the DAS.  Based on this evidence, the DAS -II and 
VABS -II will be utilized as the primary  and secondary  assessment tools for efficacy .
A model illustrating the efficacy  endpoints 
in this study is presented in Table 7-5.  The endpoints 
have been classified as primary , key  secondary , and secondary  based on 
their clinical 
importance.  Secondary  efficacy  endpoints have been included for the purposes of providing 
additional data to support both the primary and key  secondary  endpoi nts.  The change from 
baseline in GCA, as assessed by  the DAS -II, will be the primary  endpoint.  TheDAS -II will be 
used to measure secondary  endpoints
,including standardized scores in cluster areas and 
developmental quotients.  Key  secondary  and other se condary  endpoints are derived from the 
VABS -II to assess adaptive behaviors.  Page 62
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 63Table 7-5. Endpoint Model
Concept Subconcept Assessment Tool
Prim ary Endpoint
Cognitive 
FunctionGeneral Conceptual Ability (G CA) DAS II
Key Secondary Endpoint
Adaptive 
BehaviorAdaptive Behavior Composite (ABC) VABS -II
Secondary Endpoints
Cognitive 
FunctionStandardized score in DAS -II cluster areas: Verbal, 
Nonverbal, Spatial, GCA, and Special Nonverbal 
Com posite (SNC)
Developmental quotient for the following:
Group 1a
     or:Verbal Comprehension
Picture Similarities
Nam ing Vocabulary
Pattern Construction
Matrices 
Copy ingDAS II -Early Years
Group 2aRecall of Designs
Word Definition
Pattern Construc tion
Matrices
Verbal Similarities 
Sequential Reasoning 
Quantitative ReasoningDAS -II -School Age
Adaptive 
BehaviorStandardized scores and developmental quotients 
(based on age equivalents) in VABS -II dom ains:
Communication
Daily Living Skills
Soc
ialization
Motor Skills
Maladaptive BehaviorVABS -II
aThe concepts assessed w ill be dependent on the chronological age of the child. The child will be given 
the relevant version of the DAS -II(Early Years or School Age) per their age and ability. Page 63
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 648STUDY ACTIVITIES
Each activity  will be performed as specified in the Schedules of Events .  See Section 13for the 
Schedule of Events for the pivotal study  (Appendix 1 and Appendix 2 ) and separate substudy 
(Appendix 3 ).
8.1 Screening (Month -1, Week -4 to -1)
8.1.1 All Patients in the Pivotal Study and Substudy
Thefollowing procedures will be per formed up to 28 day s prior to randomization /enroll ment 
(ie,Day -28 to Day  -1):
Written informed consent (assent if applicable) b y patient’s parent(s) or legally 
authorized guardian(s) prior to any  study -related procedures
Assessment of eligibility  accordi ng to review of study  entry criteria 
Medical history
Hunte r syndrome diagnosis and genot yping .  Analy sis of iduronate -
2-sulfatase genot ype 
will be required for allpatients who have not had a previous genot yping performed at 
Greenwood Genetic Center’s Dia gnostic Laboratory  (Greenwood, South Carolina, USA).   
Even patients for whom prior genot yping was performed at Greenwood Genetic Center’s 
Diagnostic Laboratory may need have a repeat analy sis performed if the original 
information was insufficient for an u nambiguous classification of genot ype(eg, to 
document the integrity  of the FMR1 and FMR2 genes in patients with complex 
mutations/chromosomal rearrangements).
Echocardiogram (note: this assessment will not need to be performed if an 
echocardiogram taken w ithin 3 months of study  start is available and deemed satisfactory  
for evaluation of anesthesia risk. )
Physical and neurological examination
Height and weight
Head circumference
Hearing assessment
Neurodevelopmental assessments:
oDifferential Ability  Scales, Second Edition (DAS -II) 
oFor patients in the substudy  only, who are too young (<3 years of age) or unable 
to complete the DAS -II, the Bay ley Scales of Infant Development, Third Edition 
(BSID- III) 
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
12-lead ECG
Vital signs
Clinical laboratory  tests
Urinary GAG
Anti
-idursulfase antibody  testing
General anesthesia
Brain MRIPage 64
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 65ICP measurement
CSF sample collection (by  lumbar puncture)
Health status assessment (EQ- 5D)
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse events
8.2 Randomization/Enrollment : Clinic Admission (Month 0, Week 0, Day 0)
8.2.1 All Patients (IT Treatment and No IT Treatment Groups )inthe Pivotal Study
Randomization
8.2.2 All Patients in the Substudy
Docu mentation of entry  criteria for enrollment
8.3 Treatment Period ( Months 1 to 12)
During this period ,several phases of activity  will occur .  These are designated in the Schedules 
of Events as: P re-surgery, Surgery , Follow up at Weeks 2 and 3 ( Pre-surgery , Sur gery ,and Post -
op Recovery ) and Pre -treatment, IT Injection, Follow up at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 
36, 40, 44, 48 ( IT Dosing ).
8.3.1 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the 
Substudy: Surgery and Post -op Recovery (Weeks 2 and3)
IDDD placement will require surgical implantation under general anesthesia and post-surgical 
assessment .
8.3.1.1 Pre-surgery
Physical and neurological examination
Height and weight
12-lead ECG
Vital signs
Clinical laboratory  tests 
Concomitant m
edications, t herapies /interventions , and m edical/ surgical procedures
Adverse events
8.3.1.2 Surgery
Vital signs
General anesthesia
CSF sample collection
IDDD implantationPage 65
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 66X-ray(to verify  IDDD is at the mid-thoracic level in the spinal canal and correctl y 
installe d)
Concomitant medications, therapies /interventions , and 
medical/ surgical procedures
Adverse events
8.3.1.3 Follow up
Physical and neurological examination
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse events
8.3.2 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the 
Substudy: IT Dosing (Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 [±7 days])
8.3.2.1 Pre-treatment
Physical and neurological examination (performed only  at Weeks 4, 16, 2 8, 40)
Height an
d weight
Head circumference
Hearing assessment
Neurodevelopmental assessments (performed only  at W eeks 16, 28, and 40 )
oDifferential Ability  Scale s, Second Edition (DAS -II) 
oFor patients in the substudy  only, who are too young (<3 years of age) or unable 
tocomplete the DAS -II, the Bayley Scales of Infant Development, Third Edition 
(BSID- III) 
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
12-lead ECG
Vital signs
Clinical laboratory  tests (performed onl y at W eeks 4, 16, 28 and 40)
Urinary  GAG (performed only  at W eeks 4, 16, 28, 40 )
Anti- idursulfase antibody  testing
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse events
8.3.2.2 IT Injection
12-lead ECG ( performed only at W ee ks 4, 16, 28, 40)
Vital signs
CSF sample collection (performed at each IT Dosing Week prior to idursulfase -IT 
injection )
idursulfase -IT injection . Patients will remain under observation in the hospital setting 
(may  include lounge, infusion center, or waiting room) for at least 4 hours post IT
injection and will be discharged when deemed clinically  stable b y the Investigator.  The 
patient will need to be examined the following day (See Follow Up, Section 8.3.2.3) by 
the Investigator; however, there i s no requirement for an overnight hospital stay .  Note Page 66
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 67that, on I T Dosing Weeks, the IV infusion of Elaprase should be scheduled to occur a 
minimum of 48 hours after IT administration of idursulfase- IT.
Serum sampl ingfor pharmacokinetic anal ysis(performe d onl y at Weeks 4, 24, and 48). 
Samples will be collected within 15 minutes (±5 minutes) prior to intrathecal 
administration of idursulfase -IT and at 30 minutes (±5 minutes), 60 minutes (±5 
minutes), 120 minutes (±5 minutes). 4 hours (±5 minutes), 6 hours (±5 minutes), 8 hours 
(±15 minutes), 12 hours (±15 minutes), 24 hours (±15 minutes), 30 hours (±15 minutes), 
36 hours (±15 minutes) after the start of intrathecal administration.
Concomitant medications, therapies /interventions , and m edical/ surgical proce dures
Adverse events
8.3.2.3 Follow Up
Physical and neurological examination
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse events
8.3.3 Patients in the No IT Treatment Group of the Pivotal Study (Months 1 to 12)
8.3.3.1 Weeks 4, 16, 28, 40 (± 7 days)
Physical and neurological examination
Height and weight
Head circumference
Hearing assessment
12-lead ECG
Vital signs
Clinical laboratory  tests
Urinary  GAG
Anti
-idursulfase antibody  testing
Neurodevelopmental assessments ( performed only at Weeks 16, 28, and 40)
oDifferential Ability  Scales, Second Edition (DAS- II) 
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse events
8.3.3.2 Weeks 8, 12, 20, 24, 32, 36, 44, 48 (± 7 days)
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse eventsPage 67
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 688.4 End of Study: Month 13 (Week 52 [±7 days] )
8.4.1 Patients in the IT Treatment Group of the Pivotal Study and All Patients in the 
Subst udy
Physical and neurological examination
Height and weight
Head circumference
Hearing assessment
Neurodevelopmental assessments 
oDifferential Ability  Scales, Second Edition (DAS- II) 
oFor patients in the substudy  only, who are too young (<3 years of age) or unable 
to complete the DAS -II, the Bay ley Scales of Infant Development, Third Edition 
(BSID- III) 
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
12-lead ECG
Vital signs
Clinical laboratory  tests
Urinary  GAG
Anti
-idursulfase antibody  testing
General anesthesia
Brain MRI
ICP measurement
CSF sample collection
X-ray
Health status assessment (EQ -5D)
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse events
8.4.2 Patients in the No IT Treatment Group of the Pivotal Study
Physical and neurological examination
Height and weight
Head circumference
Hearing assessment
Neurodevelopmental assessments:
oDifferential Ability  Scales, Second Edition (DAS- II) 
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
12-lead E CG
Vital signs
Clinical laboratory  tests
Urinary  GAG
Anti
-idursulfase antibody  testing
General anesthesiaPage 68
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 69Brain MRI
ICP Measurement
CSF sample collection
Health status assessment (EQ -5D)
Concomitant medications, therapies /interventions , and m edical/ surgica l procedures
Adverse events
8.5 Follow-up Visit (Day 7 [±2 Days ]Post EOS )
8.5.1 All Patients in the Pivotal Study and Substudy
Thefollowing will be assessed by  telephone contact:
Concomitant medications, therapies /interventions , and m edical/ surgical procedures
Adverse eventsPage 69
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 709QUALITY CONTROL AND ASSURANCE
Training onthe study  protocol, device usage, and investigational product administration will 
occur at an Investigator meeting ,at the site initiation visit, or both.  I nstruction swill be provided 
to aid consist ency  in data collection and reporting across sites.
Clinical sites will be monitored by  the Sponsor or its designee to ensure the accuracy  of data 
against source documents.
  The required data will be captured in a validated clinical data 
management s ystem that is compliant with the FDA 21 CFR Part 11 Guidance .  The clinical trial 
database will include an audit trail to document any  evidence of data processing or activity  on 
each data field b y each user .  Users will be trained and given restricted access, ba sed on their 
role(s) in the stud y, through a password -protected environment.
Data entered in the s ystem will be reviewed manually  for validity  and completeness against the 
source documents by  a clinical monitor from the Sponsor or its designee .  If necessa ry, the study  
site will be contacted for corrections or clarifications ; all missing data will be accounted for.
Serious adverse event information captured in the clinical trial database will be reconciled with 
the information captured in the 
Pharmacovigila nce and Risk Management database .Page 70
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 7110 STATISTICAL ANALYSIS
10.1 General Methodology
Continuous variables will be summarized using descriptive statistics (N, mean, standard 
deviation, minimum, median, and maximum). Categorical variables will be summarized using 
thenumber and percentage of patients in each category . Data will be summarized with respect to 
patient disposition, demographic and baseline characteristics and concomitant medication use.  
The efficacy  endpoints, safet y assessments and other outcome result s for each treatment group 
will be summarized descriptively  unless otherwise indicated. In addition, least squares means, 
treatment differences, p -values and 95% confidence intervals for least squares mean treatment 
differences will also be provided where relevant for efficacy  endpoints.  The fit of linear models 
will be assessed using residual plots and other diagnostic plots. All the hy pothesis tests will be 
2-sided and will be performed at the 0.05 level of significance unless stated otherwise.  
The s eparate substud y is an open -label, single arm study .  Data from patients participating in this 
separate substudy  will be anal yzed separatel y.Safety  data from the single -arm substudy  will be 
summarized and efficacy data will be listed.
There are no formal hypotheses associated with the evaluation of the safet y and performance of 
the IDDD device (SOPH -
A-PORT Mini S).  All analy ses of device safety  and performance will 
be descriptive and no statistical testing will be performed.  Device related analyses will be based 
on patients for whom the device implant procedure was performed and are described below.
10.2 Determination of Sample Size
Based on stud y HGT -HIT-050/045 Phase I/II data, the observed decline in mean GCA score in 
untreated patients was estimated to be 13.7 points with a standard deviation of 9.4 after 
12months. For the sample size calculation, we conservativel y assumed an approximately  
1point per month rate of decline in the untreated control arm, so that the theoretical decline 
would be 13 points from baseline (screening) to Visit Week 52. As up to 2 months may elapse 
between the screening assessment and the start of idursulfase- IT treatment, a mean decline of 
2points at end of study  would be expected if idursulfase was effective in stabilizing th e decline. 
Therefore, in such a case, the mean projected treatment difference at Visit Week 52 would be 11 
points (ie, 13 minus 2) , which is considered a clinically  meaningful treatment difference.
Using a 2:1 randomization, a sample size of 42 randomized patients (28 I T patients, 14 control 
patients) will y ield 80% power to detect a clinically  meaningful mean treatment difference in the 
primary  endpoint, GCA change from baseline to Visit Week 52 of 11 points.  This calculation 
further assumes a common sta ndard deviation for the change from baseline of 10 points
, a ty pe-I 
error rate of 0.05 for a two- sided two- sample t -test, with approximately  up to 20% missing an 
assessment at Visit Week 52. 
After approximately  one- half of the planned number of patients ( ie, 21 patients) has completed 
the Week 52 visit, and prior to enrollment closure, a blinded assessment of overall variability  for 
the primary  endpoint will be made by estimating the pooled standard deviation. The variability  Page 71
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 72assessment will be performed by an independent statistician who is not involved in the final 
analysis of this study .  If it does not appear that the variability is consistent with the assumptions 
used in the sample size calculation, the sponsor may consider increasing the sample size by 
amending the protocol.
For the separate substudy, there is no target sample size.  A ll patients meeting eligibility  criteria 
for the substudy  will be enrolled until enrollment for the randomized trial is completed.
10.3 Method of Assigning Study Patients to Treatment Groups
Patients will be randomized (open -label, assessor -blinded) in a 2:1 allocation ratio between the 
active (idursulfase -IT treatment regimen) and control groups. Although this is a multi -center 
study , the randomization will not be stratified by center. The baseline GCA score (at Screening 
Visit) is expected to be a key  prognostic factor. Therefore, the randomization will be stratified 
according to baseline GCA score: greater than 70 versus less than or equal to 70. The 
randomization schedule will be generated and administered centrall y by a third -party (eg, IVR 
vendor) independent of the project team. There is no replacement of patients who do not 
complete the study .
In a separate substud y, additional patients may be enrolled who have a co mplex rearrangement 
genot ype in the iduronate -2 sulfatase gene and who are below the age of 3 y ears at the time of 
informed consent.  Such patients are ineligible for the randomized trial and will not be 
randomized, but will receive idursulfase -IT treatment monthly  at a dose of 10 mg.  
10.4 Population Description and Exposure
10.4.1 Analysis Populations
For the randomized trial, all efficacy  data anal yses will be performed using the I ntent- to-Treat 
(ITT) Population, which is defined as all randomized patients.  
All safet y data anal yses will be performed using the Safet y Population, which is defined as all 
randomized patients with any  post -randomization safet y assessments.  IDDD and procedure 
related anal yses will be conducted in the treated set of the Safet y Populatio n who had the device 
implant procedure performed.
All pharmacokinetic data anal yses will be performed using the PK population. The PK 
population will be defined as all patients who received study  drug and had at least one sample 
collected for pharmacokine tic anal ysis. 
For the substud y, all analyses will be performed on the Substudy  Population, defined as all 
patients enrolled and treated with study  drug in the substudy .
10.4.2 Patient Disposition
The number and percentage of patients screened, randomized, comple ting each visit of the study , 
and discontinued prematurely  by reason for withdrawal will be summarized by  treatment group Page 72
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 73for the ITT and Safet y populations in the randomized trial.  A similar summary will be provided 
for the separate substud y. 
10.4.3 Protocol Deviations
An incident involving noncompliance with the protocol, but one which ty pically  does not have 
significant effects on the patient’s rights, safet y, or welfare, or the integrity of the resultant data 
will be considered a protocol deviation. An inc ident involving noncompliance with the protocol 
which may  affect the patient’s rights, safet y, or welfare, or the integrit y of the resultant data will 
be known as a protocol violation. In particular, any  serious deviation that affects the collection 
of da ta for the primary  endpoint will be considered a protocol violation. 
Examples of potential protocol violations may include violation of important admission 
(inclusion/exclusion) criteria, occurrence of a treatment dispensing error, treatment 
noncompliance or substantial use of a prohibited medication during the study .  Reported protocol 
deviations and patient data will be examined prior to database lock to determine if conditions set 
forth in the study  protocol have been violated and a more comprehensive l ist will be constructed 
at that time.  The list of protocol deviations will not be presented; however, identified protocol 
violations will be summarized.
10.4.4 Demographics and Baseline Characteristics
Demographic and baseline characteristics ( eg,genoty pe, age [years], race, ethnicity , weight [kg], 
height [cm], BMI [kg/m2], country , medical history ) will be summarized by treatment group in 
the randomized trial.  A similar summary  will be provided for the separate substudy .
10.4.5 Treatment Compliance
Treatment complian ce will be summarized in terms of the percent of scheduled doses received in 
the idursulfase -IT arm.  Percent compliance is defined as: 
[(No. of Complete I T injections Received) ÷ (Expected No. of IT injections at EOS)] *100.
10.4.6 Extent of Exposure 
The numbe r of IT injections received overall and by  lumbar puncture, average dose, the duration 
of idursulfase -IT treatment and IT administration duration will be summarized descriptively in 
the idursulfase -IT arm. The duration of idursulfase -IT treatment, summari zed in months, is 
defined as the time from first to last I T administration during the study .  The duration for each 
idursulfase -IT administration (in minutes) is calculated by  subtracting the administration start 
time from the administration end time.
10.5 Anal ysis of Efficacy
All analy ses described below refer to the randomized trial; all efficacy  data from patients treated 
in the separate substudy  will be listed only , including composite scores, age equivalents and 
development quotients as measured b y the BSID -III.Page 73
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 7410.5.1 Primary Efficacy Endpoint Analysis
For the randomized trial, the primary  efficacy  endpoint is the change from study  baseline 
(screening visit) to Visit Week 52 in the General Conceptual Ability  (GCA) score as measured 
by the DAS -II.  The primary  anal ysis will compare the treatment groups using a linear mixed 
model repeated measures (MMRM) anal ysis.22  The repeated measures are the change from 
baseline GCA scores obtained at the scheduled Visit Weeks 16, 28, 40, and 52, respectivel y.  
The model will include fixed categorical effects for treatment, visit week, treatment b y visit 
week interaction, and a GCA classification factor (based on baseline GCA score ( ≤70 
or >70) 
and the GCA classification factor b y treatmen t interaction.  The GCA classification factor b y 
treatment interaction term will be included in the model if the interaction is significant at the 
10% level; otherwise, the MMRM analy sis without this interaction will be considered the final 
primary  model. SAS Proc Mixed with restricted maximum likelihood estimation (REML ) and 
an unstructured within-patient covariance structure will be used.  If this model fails to converge, 
a first order autoregressive (AR(1)) covariance structure will be used for the prim ary anal ysis.
The Kenward
-Roger approximation will be used to estimate denominator degrees of freedom for 
tests of fixed effects.  
From this model, least squares means, standard errors, treatment differences in least squares 
means, and 95% confidence intervals and p -values will be estimated for each time point.  
Significance tests will be based on the difference in least squares means.  Primary  inference is 
based on the treatment comparison at Visit Week 52 from this model. The null hy pothesis is that 
the mean difference in the primary  endpoint between the two treatment groups is zero, versus the 
alternative h ypothesis that this difference is not zero. The h ypotheses can be expressed as 
follows:
H0: μ IT- μcontrol = 0  versus  H1: μ IT- μcontrol ≠ 0
Whe re μITrefers to the mean change from baseline to Visit Week 52 in GCA score in the 
idursulfase -IT treated group and μ control refers to the mean change from baseline to Visit Week 
52 in GCA score in the untreated control group. The test will be performed using the final, 
MMRM model -based t -
test with a two-sided significance level of 5%. Similar secondary  
treatment comparisons from this model at Visit Weeks 16, 28, and 40 will also be presented. 
Estimated least squares means by  treatment group will be plo tted over time.
10.5.2 Key Secondary Efficacy Endpoint Analysis
The key  secondary  efficacy  endpoint is the change from study  baseline ( Screening Visit) to Visit 
Week 52 in the Adaptive Behavior Composite (ABC) score as measured by the VABS -II.  The 
key secondary  analy sis will compare the treatment groups using a linear mixed model repeated 
measures (MMRM) analy sis.  The repeated measures are the change from baseline ABC scores 
obtained at the scheduled Visit Weeks 16, 28, 40, and 52, respectivel y.  The model will include 
effects of treatment, visit week, treatment b y visit week interaction and the baseline ABC score 
as a continuous covariate. The baseline ABC score by  treatment interaction will be included in 
the model if the interaction is significant at the 10% level; otherwise, the MMRM analy sis 
without this interaction will be considered the final model for this endpoint.  SAS Proc Mixed Page 74
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 75with restricted maximum likelihood estimation (REML ) and an unstructured within -patient 
covariance structure will be used.  I f this model fails to converge, a first order autoregressive 
(AR(1)) covariance structure will be used instead. The Kenward- Roger approximation will be 
used to estimate denominator degrees of freedom for tests of fixed effects.  From this model, 
least squ ares means, standard errors, treatment differences in least squares means, and 95% 
confidence intervals and p -values will be estimated for each time point. The inferential test of 
the key  secondary  endpoint is based on the treatment comparison at Visit We ek 52 from this 
model.
10.5.3 Other Secondary Efficacy Endpoints Analyses
The following secondary efficacy  endpoints will be anal yzed using an MMRM analy sis in the 
same manner as described above for the key  secondary  endpoint with the continuous covariate 
corresp onding to the baseline score for each measure: 
(1) The change from baseline to Visit Weeks 16, 28, 40, and 52 in standardized scores in cluster 
areas of the DAS -II: Verbal, Nonverbal, Spatial, and Special Nonverbal Composite (SNC) 
(2) The change from bas eline to Visit Weeks 16, 28, 40, and 52 in the standardized domain 
scores of the VABS -II: Communication, Daily  Living Skills, Socialization, Motor Skills, and 
Maladaptive Behavior.  
All other secondary  efficacy  endpoints will be summarized descriptively  by treatment group. 
Mean values b y treatment group will be plotted over time. This includes the following 
endpoints:
(1) The change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents and 
development quotients for the subcategories of th e DAS -II: Verbal Comprehension, Picture 
Similarities, Naming Vocabulary , Pattern Construction, Matrices and Copying for the DAS
-
II/Earl y Years; and Recall of Designs, Word Definitions, Pattern Construction, Matrices, Verbal 
Similarities and Sequential and Quantitative Reasoning for the DAS -II/School Years
(2) The change from baseline to Visit Weeks 16, 28, 40, and 52 in the age equivalents and 
developmental quotients in domains of the VABS -II: Communication, Daily Living Skills, 
Socialization, Motor Skills, and Maladaptive Behavior.
10.5.4 Exploratory Subset Analyses
Subgroup anal yses are planned for exploratory  purposes.  Patients with a baseline GCA score of 
greater than 70 will be classified as having “Moderate” cognitive impairment, whilst patients 
with a basel ine GCA score equal to or below 70 will be classified as having “Severe” cognitive 
impairment.  The randomization is stratified by  this classification variable to ensure treatment 
group balance within these subgroups. The primary  endpoint model (MMRM) also includes 
baseline GCA score ( ≤70 or >70) as a factor.  The treatment b y baseline GCA factor interaction 
will be tested using this model at the 10% significance level.  Descriptive statistics for the 
primary  endpoint will be presented by  treatment within ea ch GCA subgroup (Moderate v ersus
Severe cognitive impairment ,as described above).  The baseline GCA factor by  Visit interaction Page 75
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 76and the three -way interaction of treatment, baseline GCA factor and Visit will likewise be 
investigated for this model.  Simila r exploratory  subset anal yses of the primary  endpoint may  be 
performed for age ( ≤6 years versus >6 y ears), country , native language (Spanish versus English 
speaking region) or other baseline factors using MMRM.
10.6 Pharmacokinetic, Pharmacodynamic and Health Status Outcomes
10.6.1 P harmacokinetic Measurements and Parameters
The pharmacokinetic concentrations and derived pharmacokinetic parameters will be anal yzed 
by the sponsor staff in the Clinical Pharmacology  and Pharmacokinetics group and reported 
separately  in a pharmacokinetic report to be appended to the Clinical Study  Repor t.  
Accordingl y, the planned anal yses related to those data are described elsewhere.
10.6.2 Pharmacodynamic Outcome
Urine and CSF GAG levels, and the change from baseline ( Screening Visit) will be summarized 
by visit and treatment group.  Mean values will be plot ted over time.  A Wilcoxon Rank Sum test 
will be used to compare treatment groups on the CSF GAG change from baseline to the Week 
52/EOS visit.
10.6.3 Health Status Outcome
The EQ -5D measures 5 dimensions of health status: mobility , self -care, usual activities, 
pain/discomfort, and anxiety /depression. For each dimension, there are 3 levels of response: 
no problems 
some problems
severe problems. 
The number and percent of patients with each response will be presented b y dimension at each 
visit.  The visual anal ogue scale (VAS) records the patient’s parent/caregiver -rated health on a 
0(worst health) to 100 (best health) scale. The VAS score, as well as the change from baseline 
(screening visit to Week 52/EOS) will be summarized. A Wilcoxon Rank Sum test will b e used 
to compare treatment groups on the change from baseline to Week 52/EOS visit in VAS score.  
Pharmacoeconomic analyses may  be performed by  the sponsor staff in the Health 
Economics
and Outcomes Research g roup and reported separately  in a pharmacoecon omic report to be 
appended to the Clinical Study  Report. Accordingl y, an y planned pharmacoeconomic anal yses 
related to this data may  be described elsewhere.
10.7 Safety Assessments
All safet y anal yses will be descriptive, no statistical testing will be perform ed.  All anal yses 
described below refer to the randomized trial; safety data from the separate substudy  will be 
similarly  summarized where relevant.Page 76
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 7710.7.1 Adverse Events
10.7.1.1 Adverse Events
Adverse event s will be recorded throughout the study  and at early  termination .  Adverse event s 
and medical conditions will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA) version 12.1 or later.  Adverse events occurring on or after randomization and on or 
before the follow -up visit (7 day s after EOS) will be summarized by
 treatment group, both 
overall and within s ystem organ class by  preferred term.  Adverse events will also be tabulated 
by highest severity  (mild, moderate, severe) and by  closest relationship to study  drug (not 
related, related) for treated patients.  A separate tabulation of IV Elaprase infusion- related 
adverse events will also be presented.  In addition, those events which resulted in death or were 
otherwise classified as serious will be summarized and presented in a separate listing.
10.7.1.2 IDDD and Procedure Related Adverse Events
IDDD and procedure related adverse events will be summarized within sy stem organ class b y 
preferred term.  Adverse events will be tabulated by  severit y (mild, moderate, severe) and degree 
of relatedness.  Separate tabul ations will be provided for adverse events related to the IDDD, 
device surgical procedure and IT -administration process.  IDDD and procedure related events 
will be anal yzed in the set of treated patients in the Safety  Population with device implanted.
10.7.2 Clinical Laboratory Evaluations
Laboratory values (chemistries, hematology , and urinaly sis), including CSF components 
(standard chemistries, glucose, protein, and cell counts) will be summarized in terms of the 
absolute value and change from baseline at each t ime point by  treatment group.  The number and 
percentage of patients with clinically  significant post -baseline laboratory  results will be 
presented b y treatment group.  
10.7.3 ECG Evaluations
The 12- lead ECG parameters (sinus rh ythm, atrial or ventricular h ypertrophy , heart rate [bpm], 
pulse rate interval [msec ], QRS interval [ msec ], QT interval [msec ]and the corrected QTc 
[msec ]
interval) will be summarized in terms of absolute value and change from baseline.  The 
number and percentage of patients with clinica lly significant post- baseline ECG results will be 
presented b y treatment group.
10.7.4 Vital Signs and Physical Measurements
Vital signs (temperature [C], pulse [bpm] , blood pressure [ systolic and diastolic , mmHg ], and 
respiration 
[per min] ), and the change from baseline ( Screening Visit) will be summarized 
graphicall y by study  time point and treatment group.  
Height (cm), weight (kg) ,and head circumference (cm) and the change from baseline ( Screening 
Visit) will be summarized by  study  time point and treatment g roup.  ICP measurement (cm of 
H2O) and brain MRI volumes will be similarly  summarized.Page 77
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 7810.7.5 Physical Findings
Physical and neurological examination findings will be listed for all patients.
10.7.6 Other Observations Related to Safety
10.7.6.1 Hearing Assessments
The number and percentage of patients in the hearing assessment categories (hearing aid, right 
ear test results, left ear test results, right ear level of hearing loss and left ear level of hearing 
loss) will be summarized by treatment group, and visit. The number and percentage of patients 
with abnormal hearing assessments will be summarized by  study  time point and treatment group .
10.7.6.2 Immunogenicity
Anti- idursulfase antibody  formation will be monitored throughout the study  for both serum and 
CSF in the I dursulfase -IT trea tment group.  The number and percentage of patients testing 
anti-idursulfase antibod y positive and negative at each time point will be summarized.  Titer 
values will be summarized and means plotted over time.
10.7.6.3 Device Performance
SOPH -A-PORT safet y and perfo rmance will be summarized for implanted patients. Difficulties 
associated with the implant procedure ( eg,excessive bleeding, CSF leakage, etc) will be 
summarized.  A summary of abnormal findings from the IDDD radiological assessments will 
also be present ed.  
The proportion of patients with at least one IDDD failure and the proportion with malfunction 
only, as well as the number of and reasons for IDDD failures and malfunctions and actions taken 
will be summarized.  The rate of IDDD failures and malfuncti ons and the corresponding 95% 
confidence interval will also be estimated.  The time from initial implant surgery  to first IDDD 
failure and the time to malfunction only  will be analy zed using Kaplan -Meier Life Table 
methods.  Patients without an IDDD failur e or malfunction will be censored at their last study  
drug injection date.  A b y-patient listing of the device failure and malfunction data will be 
display ed.
The proportion of patients for whom a successful first injection of study  drug occurred will be 
summarized among those for whom a first injection was attempted ( ie,those who had an 
apparentl y successful implantation and did not suffer a device removal or revision prior to first 
scheduled injection).  The proportion of patients who had no failed injec tion attempts during the 
study  will also be summarized. The corresponding 95% confidence intervals of the proportion of 
interest will be estimated, where appropriate. Injections not given for patient reasons ( eg, patient 
uncooperative, competing medical issue, etc) will not be included in the determination of these 
estimates.  The frequency and reasons for unsuccessful injection attempts will be reported.  Page 78
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 7910.7.7 Concomitant Medications
Concomitant medications are defined as all medications taken on or after t he time of the 
randomization and on or before the last follow up date (EOS Visit date plus 7 day s). 
Concomitant medications will be mapped using the WHO drug dictionary  and summarized by  
the therapeutic class and preferred term for each treatment group.
10.8 Statistical/Analytical Issues
10.8.1 Handling of Drop -outs and Missing Data
In general, no imputation will be used for descriptive anal yses, or for primary  and secondary  
efficacy  anal yses utilizing MMRM methodology .  A possible exception is for randomized 
patients who discontinue earl y from the stud y. For these patients, their early  EOS efficacy  
evaluations will be used for the next scheduled time point only if the EOS evaluation is 
performed within 45 days of the next scheduled visit.  For sensitivity  anal yses us ing the 
Wilcoxon Rank- Sum test at the Week 52 Visit, the most conservation or lowest score will be 
imputed for missing data as a sensitivity  analy sis for the primary  and key  secondary  endpoints.   
Imputation methods will be described in the prospective stat istical anal ysis plan .
10.8.2 Adjustment for Covariates
As the randomization of the study  is stratified b y the baseline GCA classification factor ( ≤70 or
>70), the primary  MMRM analy sis of the change from study  baseline to Visit Week 52 in GCA 
score will take into account the GCA score as a classification facto r.In addition, for a 
supportive anal ysis, a similar MMRM analy sis will be performed adjusting for the baseline GCA 
score as a continuous covariate.  Key  secondary  and secondary  anal yses of the change from 
baseline in efficacy  scores utilizing MMRM method ology  will adjust for the baseline score of the 
parameter of interest as a continuous covariate in the model.  Exploratory  MMRM analy ses to 
evaluate treatment interactions or other interactions and to identify potential predictors of 
efficacy  outcome may  also utilize covariate adjustment.
10.8.3 Interim Analysis
No formal interim anal ysis or interim statistical testing is planned. The DSMB will monitor 
safet y data periodicall y during the trial.  A pooled, blinded assessment of the overall variability 
of the prima ry endpoint will be conducted during the study  in order to assess the appropriateness 
of the variabilit y assumption used in the sample size calculation.  Following the completion of 
the study  and collection and verification of all final data, the database will be locked and the 
results of the planned statistical analy sis will be described in a final study  report.
10.8.4 Multicenter Studies
This is a multicenter study utilizing a central randomization.  I t is planned that the data from all 
centers that participate in this protocol will be combined so that an adequate number of patients 
will be available for analysis.  Because of the potential for a relatively large number of centers, Page 79
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 80and small numbers of patients at some centers, no subset anal yses by center are pla nned. No 
adjustment for center effect will be utilized in the statistical analy ses.
10.8.5 Multiple Comparisons/Multiplicity
The overall ty pe I error rate for tests of the primary and key  secondary  endpoints will be 
controlled at 0.05.  To control an overall ty pe I error rate at this level for the two tests, a fixed 
sequential testing procedure will be followed.  The null hy pothesis of no treatment difference for 
the primary  endpoint will be tested first.  The null hy pothesis of no treatment difference for the 
key secondary  endpoint then may  only  be rejected if the null hy pothesis for the primary  endpoint 
is first 
rejected.  
All other secondary  endpoints and time points are considered supportive and treatment 
comparisons will be made without adjustment for multip licity .  The resulting p- values from these 
supportive anal yses will be interpreted descriptively  as summarizing the weight of evidence for a 
treatment difference and may  suggest avenues for further exploratory  anal yses or generate formal 
hypotheses to be t ested in future trials.
10.8.6 Sensitivity Analyses
As a sensitivity  anal ysis of the primary  endpoint, the Wilcoxon Rank -Sum test will be used to 
compare treatment groups at Visit Week 52.  This test is based on the ranked changes from 
baseline.  Patients who ter minate the study  early or who have a Week 52 visit, but are not able to 
complete the GCA assessment for an y reason, including either low cognitive ability or 
behavioral problems during the assessment, will have the rank of their change from baseline 
impute d to the lowest possible value, to represent the worst possible outcome.  This imputation 
method was chosen because a missing score may  be indicative of low cognitive function and/or 
behavioral issues.  The same sensitivity  analy sis using the Wilcoxon Rank -Sum test as described 
above for the primary  endpoint will also be performed for the key  secondary  endpoint.Page 80
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 8111ADMINISTRATIVE CONSI DERATIONS
11.1 Investigators and Study Administrative Structure
Before initiation of the study , the Investigator must provide the S ponsor with a completed Form 
FDA 1572
or Investigator Agreement .  Investigational product may be administered only  under 
the supervision of the Investigators and Sub- investigators listed on these forms .  Curriculum 
vitae must be provided for the Investigat
ors and Sub-investigators listed on Form FDA 1572 or 
the Investigator Agreement.  I f the study  involves use of an investigational device and the study  
is being conducted in compliance with 21 CFR 812, the Sponsor will obtain a signed agreement 
from each pa rticipating investigator per the requirements of 21 CFR 812.43 (c) .
The Investigator should ensure that all persons assisting with the study  are adequatel y informed 
about the protocol, an y amendments to the protocol, the study  treatments, and their study related 
duties and functions.  The Investigator must maintain a list of Sub- investigators and other 
appropriatel y qualified persons to whom he or she has delegated significant study  related duties.
The Principal Investigator for this study  is Joseph Muenz er, MD, PhD, Professor at the 
Departments of Pediatrics and Genetics, School of Medicine, Universit y of North Carolina at 
Chapel Hill ( North Carolina ,USA ).
11.2 Institutional Review Board or Independent Ethics Committee Approval
Before initiation of the study ,the Investigator must provide the Sponsor with a copy  of the 
written I RB/IEC approval of the protocol and the informed consent form . This approval must 
refer to the informed consent form and to the study  title, study  number, and version and date of 
issue of the study  protocol, as given by  the Sponsor on the cover page of the protocol.
Status reports must be submitted to the I RB/IEC at least once per year. The I RB/IEC must be 
notified of completion of the study ; afinal status report must be provided to t he IRB/IEC within 
3 months of study  completion or termination (or as required).  Copies of the status reports will be 
sent to the study  clinical monitor .  The I nvestigators must maintain an accurate and complete 
record of all submissions made to the IRB/IE C, including a list of all reports and documents 
submitted .  Drug -related adverse events which are reported to the US FDA or other regulatory  
agencies (IND Safet y Reports) and UADEs reported to regulatory  agencies must be submitted 
promptly  to the IRB/IEC.   Unexpected adverse device events will be reported to regulatory  
agencies by Sophy sa consistent with relevant regulations.  Copies of UADE reports will be 
submitted to the I RB/IEC in a timely  fashion.
11.3 Ethical Conduct of the Study
The procedures set out in this study  protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the Sponsor and Investigators abide by  
Good C linical Practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the 
Internati onal Conference on Harmonisation (ICH) GCP Guidelines Compliance with these Page 81
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 82regulations and guidelines also constitutes compliance with the ethical principles described in the 
Declaration of Helsinki.
11.4 Patient Information and Consent
Before enrolling in the clinical study , the patient or the patient’s parent( s) or legally  authorized 
representative(s) , as appropriate, must consent to participate after the nature, scope, and possible 
consequences of the clinical study have been explained in a form understandab le to him or her.
An informed consent form (assent form if applicable) that includes information about the study  
will be prepared and given to the patient or the patient’s parent (s) or legall y authorized 
representative(s) .  This document will contain all F DA and ICH -required elements.  The 
informed consent (or assent , if applicable ) form must be in a language understandable to the 
patient or the patient’s parent( s) or legally  authorized representative(s) and must specify  who 
informed the patient, the patient’s parent(s), or the patient’s legall y authorized representative(s).
After reading the informed consent document, the patient or the patient’s parent (s) or legall y 
authorized representative(s) must give consent in writing.  Consent (or assent, if applicab le)must 
be confirmed at the time of consent b y the personally  dated signature of the patient, the patient’s 
parent(s) or the patient’s legally  authorized representative(s) and by  the personally  dated 
signature of the person conducting the informed consent discussions.
If the patient or the patient’s parent (s) or legall y authorized representative(s) is unable to read, 
oral presentation and explanation of the written informed consent form and information to be 
supplied must take place in the presence of an i mpartial witness
.  Consent (or assent, if 
applicable) must be confirmed at the time of consent orally  and b y the personally  dated signature 
of the patient or b y a local legall y recognized alternative (eg, the patient’s thumbprint or mark) 
or by  the persona lly dated signature of the patient’s parent(s) or the patient’s legally  authorized 
representative .  The witness and the person conducting the informed consent discussions must 
also sign and personall y date the informed consent document
.  It should also be recorded and 
dated in the source document that consent (or assent, if applicable) was given.
A cop y of the signed and dated consent document(s) must be given to the patient or the patient’s 
parent (s) or legal representative(s) .  The original signed and dat ed consent document will be 
retained b y the Investigator.
The Investigator will not undertake any  measures specificall y required solely for the clinical 
study  until valid consent (or assent, if applicable) has been obtained.
A model of the informed consent form to be used in this study  will be provided to the sites 
separately  from this protocol.
11.5 Patient Confidentiality
Patient names will not be supplied to the Sponsor .  Only  the patient number (and in some 
regions, 
patient initials) will be recorded in the eCRF , and if the patient name appears on an y 
other document, it must be obliterated before a copy  of the document is supplied to the Sponsor .  Page 82
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 83Study  findings stored on a computer will be stored in accordance with local data protection laws .  
The patients w ill be told that representatives of the Sponsor, a designated CRO, the I RB/IEC, or 
regulatory  authorities may  inspect their medical records to verify  the information collected, and 
that all personal information made available for inspection will be handled in strictest confidence 
and in accordance with local data protection laws .  The Investigator will maintain a personal 
patient identification list (patient numbers with the corresponding patient names) to enable 
records to be identified.
11.6 Study Monitoring
Monitoring procedures that comply  with current GCP guidelines will be followed .  Review of 
the 
eCRF 's for completeness and clarit y, cross -checking with source documents, and clarification 
of administrative matters will be performed.
The study  will be monito red b y the Sponsor or its designee .  Monitoring will be performed b y a 
representative of the Sponsor (Clinical Study  Monitor) who will review the eCRF s and source 
documents .  The site monitor will ensure that the investigation is conducted according to 
protocol design and regulatory  requirements by  frequent site visits and communications (letter, 
telephone, and facsimile).
11.7
Case Report Forms and Study Records
Case report forms (paper or electronic) are provided for each patient .  All forms must be filled 
outby authorized study  personnel
.  All corrections to the original eCRF entry  must indicate the 
reason for change .  The Investigator is required to sign the eCRF after all data have been 
captured for each patient .  If corrections are made after review and si gnature by  the Investigator, 
he or she must be made aware of the changes, and his or her awareness documented by  resigning 
the 
eCRF .
11.7.1 Critical Documents
Before the Sponsor initiates the trial ( ie,obtains informed consent (and assent ,if applicable ) 
from the first patient), it is the responsibility  of the I nvestigator to ensure that the following 
documents are available to Shire HGT or their designee:
Applicable local regulatory  documentation (eg, FDA 1572 Form); signed, dated, and 
accurate
Curricula vitae o f Investigator and Sub-investigator(s) (current, dated and signed within 
24months of study  initiation)
Copy of Investigator and S
ub-investigator (s) current medical license (indicating license 
number and expiration date)
Signed and dated agreement of the f inal protocol
Signed and dated agreement of an y amendment(s), if applicable
Approval/favorable opinion from the IRB/IEC clearly  identify ing the documents 
reviewed b y name, number and date of approval or re approval:  protocol, any  Page 83
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 84amendments, Subject Infor mation/I nformed Consent Form, and any  other written 
information to be provided regarding subjects recruitment procedures
Copy  of IRB/IEC approved Subject Information/Informed Consent Form/any  other 
written information/advertisement (with I RB approval stamp and date of approval)
Current list of I RB/IEC Committee members/constitution (dated within 12 months prior 
to study  initiation)
Financial Disclosure Form signed b y Investigator and Sub- investigator (s)
Current laboratory  reference ranges (if applicable)
Certification/QA scheme/other documentation (if applicable)
Regulatory  approval and notification as required must also be available .  The protocol will not be 
initiated until regulatory  approval and notification are obtained; these are the responsibility  ofthe 
Sponsor .
11.8 Data 
Safety Monitoring Board
An independent , external DSMB will be established to provide an ongoing, independent review 
and assessment of the safety  data, and to safeguard the interests and safet y of the participating 
patients in the study .  
The DSMB will be notified of all IDDD failures and IDDD -
related complications at times 
defined in the DSMB charter.
The DSMB will consist of a biostatistician and two clinical experts.  The DSMB will adhere to a 
prospectivel y determined charter, which w ill be written by  Shire HGT and approved by  the 
DSMB .  The charter will define the responsibilities of the D SMB and Shire HGT, describe the 
conduct of the meetings, and define the data sets to be reviewed.  Serious adverse events and 
other data will be dis tributed to the members of the D SMB periodically  for review.
The first meeting of the DSMB will be an orientation meeting and will be held prior to the start 
of the study .  Thereafter, it is anticipated that the DSMB will meet at least annually .  The DSMB 
will keep detailed minutes of their discussions during the meetings, which will be kept in strict 
confidence.
11.9 Device Failure Adjudication Process
The final cause for device failures will be adjudicated by  a Shire team by  examining the clinical 
database, sa fety database, and manufacturer investigation of returned devices.
11.10 Protocol Violations/ Deviations
Any violation of the protocol as described can be considered a protocol violation including not 
meeting inclusion/exclusion criteria during the study , not adh ering to the study  treatment and 
other issues of noncompliance.Page 84
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 85The Investigator will conduct the study  in compliance with the protocol. The protocol will not 
be initiated until the I RB/IEC and the appropriate regulatory  authorities have given 
approval/fa vorable opinion .  Modifications to the protocol will not be made without agreement 
of the Sponsor
.  Changes to the protocol will require written IRB/IEC approval/favorable opinion 
prior to implementation, except when the modification is needed to eliminate an immediate 
hazard(s) to patients
.  The I RB/IEC may  provide, if applicable regulatory  authorities permit, 
expedited review and approval/favorable opinion for minor change(s) in ongoing studies that 
have the approval/favorable opinion of the I RB/IEC. TheSponsor will submit all protocol 
modifications to the regulatory  authorities in accordance with the governing regulations.
A record of patients screened, but not entered into the study , is also to be maintained .  No 
protocol exemption will be granted for 
this study .
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
patients, the Investigator will contact the Sponsor or its designee, if circumstances permit, to 
discuss the planned course of action .  An y departures from the protocol must be fully  
documented as a protocol deviation.  Protocol deviations will need to be reviewed b y the medical 
monitor and may  also be required to be submitted to the I RB/IEC .
Protocol modifications will only  be initiated by  the Sponsor 
and must be approved b y the 
IRB/IEC and submitted to the FDA or other applicable international regulatory  authority  before 
initiation.
11.11 Premature Closure of the Study
If the Sponsor, Investigator, DSMB , or regulatory  authorities discover conditions arising during 
the study  which indicate that the clinical investigation should be halted due to an unacceptable 
patient risk, the study  may  be terminated after appropriate consultation between the Sponsor and 
the Investigator(s) .  In addition, a decision on the pa rt of the Sponsor to suspend or discontinue 
development of the investigational product may be made at any  time .  Conditions that may  
warrant termination of the study
 or site include, but are not limited to:
The discovery  of an unexpected, significant, or u nacceptable risk to the patients enrolled 
in the study
Failure of the Investigator to comply  with pertinent global regulations
Submission of knowingly  false information from the study  site to the Sponsor or other 
pertinent regulatory  authorities
Insufficie nt adherence by the I nvestigator to protocol requirements
11.12 Access to Source Documentation
Regulatory  authorities, the I RB/IEC, and the Sponsor (or its representatives) may request access 
to all source documents, eCRF s, and other stud y documentation for onsite audit or inspection . 
Direct access to these documents must be guaranteed b y the Investigator, who must provide 
support at all times for these activities .  Monitoring and auditing procedures that comply  with 
current GCP guidelines will be followed
. On-site review of the eCRF s for completeness and Page 85
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 86clarity , crosschecking with source documents, and clarification of administrative matters may be 
performed.
11.13 Data Generation and Analysis
The clinical database will be developed and maintained b y a contract research organization or an 
electronic data capture technology  provider as designated by  Shire HGT. Shire HGT or its 
designee will be responsible for performing study  data management activities. 
Adverse events will be coded using Medical Dictionary  for Regulatory  Activities (MedDRA) . 
Concomitant medication will be coded using WHO Drug Dictionary  (WHO -DD). Centralized
laboratories will be employ ed as described in the study  manual to aid in consistent measurement 
of efficacy  and safety  parameters.  
11.14 Retention of Data
Essential documents should be retained until at least 2 y ears after the last approval of a 
marketing application and until there are no pending or contemplated marketing applications or 
at least 2 y ears have elapsed since the formal discontinuati on of clinical development of the 
investigational product.  The Sponsor will notify  the Investigator if these documents must be 
retained for a longer period of time .  It is the responsibility  of the Sponsor to inform the 
Investigator or institution as to w hen these documents no longer need to be retained.
11.15 Financial Disclosure
The Investigator should disclose an y financial interests in the Sponsor as described in 21 CFR 
Part 54 prior to beginning this study .  The appropriate form will be provided to the Investigator 
by the Sponsor, which will be signed and dated b y the Investigator, prior to the start of the study .  
Changes in status concerning financial interests during the study  and after its completion will be 
disclosed by the Investigator in accordance 21CFR Part 54.
11.16 Publication and Disclosure Policy
All information concerning the stud y material, such as patent applications, manufacturing 
processes, basic scientific data, and formulation information supplied by  the Sponsor and not 
previously  published are considered confidential and will remain the sole propert y of the 
Sponsor .  The Investigator agrees to use this information only  in accomplishing this study  and 
will not use it for other purposes.
It is understood by  the Investigator that the information d eveloped in the clinical study  may  be 
disclosed as required to the authorized regulatory  authorities and governmental agencies .  In 
order to allow for the use of the information derived from the clinical studies, it is understood 
that there is an obligatio
n to provide the Sponsor with complete test results and all data 
developed in the stud y in a timely manner.
The Investigator and an y other clinical personnel associated with this study  will not publish the 
results of the study , in whole or in part, at an y time, unless they  have consulted with Shire HGT, Page 86
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 87provided Shire HGT a copy  of the draft document intended for publication, and obtained Shire 
HGT’s written consent for such publication.  All information obtained during the conduct of this 
study  will be reg
arded as confidential .  Page 87
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 8812LIST OF REFERENCE S
1.Meikle PJ, Hopwood JJ, Clague AE, Carey  WF. Prevalence of l ysosomal storage disorders. 
JAMA 1999;281:249 -54.
2.Young ID, Harper PS. Incidence of Hunter's s yndrome. Hum Genet 1982;60:391-2.
3.Beck M. Mucopol ysaccharidosis ty pe II (Hunter syndrome): clinical picture and treatment. 
Curr Pharm Biotechnol 2011.
4.Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopol ysaccharidosis II 
(Hunter s yndrome). Pediatr 2008;121:e377 -86.
5.Neufeld E, M uenzer J. The Mucopol ysaccharidoses. In: Scriver CR, Beaudet AL , Sly WS, 
Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: 
McGraw -Hill; 2001:4 v. (xivii, 6338, I -104 p.).
6.Martin HR, Poe MD, Reinhartsen D, et al. Method s for Assessing Neurodevelopment in 
Lysosomal Storage Diseases and Related Disorders: a Multidisciplinary  Perspective. Acta 
Paediatr Supp 2008;97:69-75.
7.Wraith EGR, Burton BK, Muenzer J, Clarke JT, Meirleir L De, Kroepfl T, Malm G, Beck M. 
Early Clinical M anifestations in Patients Diagnosed with Hunter Sy ndrome: Data from the 
Hunter Outcome Survey . Arch Dis Child 2008;93:1.
8.Young ID, Harper PS, Newcombe RG, Archer IM. A clinical and genetic study of Hunter's 
syndrome. 2. Differences between the mild and sev ere forms. J Med Genet 1982;19:408-11.
9.Holt JB, Poe MD, Escolar ML . Natural progression of neurological disease in 
mucopoly saccharidosis ty pe II. Pediatr 2011;127:e1258
-65.
10.Holt J, Poe MD, Escolar ML . Earl y clinical markers of central nervous s ystem involv ement 
in mucopoly saccharidosis ty pe II. J Pediatr 2011;159:320- 6.e2.
11.Froissart R, Moreira da Silva I , Guffon N, Bozon D, Maire I. Mucopoly saccharidosis ty pe II-
-genoty pe/phenot ype aspects. Acta Paediatr Supp 2002;91:82-7.
12.Guffon N, Bertrand Y, Forest I, Fo uilhoux A, Froissart R. Bone marrow transplantation in 
children with Hunter s yndrome: outcome after 7 to 17 y ears. J Pediatr 2009;154:733-7.
13.Muenzer J, Beck M, Eng CM, et al. Multidisciplinary  management of Hunter s yndrome. 
Pediatr 2009;124:e1228 -39.
14.Muenz er J, Gucsavas -Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II 
clinical trial of enzy me replacement therapy  in mucopoly saccharidosis II (Hunter s yndrome). 
Mol Genet Metab 2007;90:329 -37.Page 88
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 8915.Wraith JE, Scarpa M, Beck M, et al. Mucopol ysacharidosis ty pe II (Hunter sundrome): a 
clinical review and recommendations for treatment in the era of enzy me replacement therapy . 
Eur J Pediatr 2008;167:267-77.
16. Elliot CD. The Differential Abilities Scales (DAS) San Antonio, TX The Psychological 
Corporation; 1995.
17.Young ID, Harper PS. The Natural History  of the Severe Form of Hunter's Sy ndrome: a 
Study  Based on 52 cases. I n: Dev Med Child Neurol; 1983:481 -9.
18. Sparrow S, Balla D, Cicchetti D. Vineland Adaptive Behavior Scales (Second Edition). 4201 
Woodland Road Ci rcle Pines, MN 55014- 1796: American Guidance Service, Inc; 2005.
19.Bayley N. Bay ley Scales of Infant and Toddler Development. 3 ed. San Antonio, TX The 
Psychological Corporation; 2005.
20.EuroQol --a new facility  for the measurement of health -related quality  of life. The EuroQol 
Group. Health Policy  1990;16:199 -208.
21.Rabin R, de Charro F. EQ -5D: a measure of health status from the EuroQol Group. Annals of 
medicine 2001;33:337-43.
22.Malinckrodt C, Lane P, Schnell D, Peng Y, Mancuso J. Recommendations for the Primary  
Analy sis of Continuous Endpoints in L ongitudinal Clinical Trials. Drug Inf J 2008;42:303 -
19.Page 89
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013
Shire Confidential 93Appendix 2 Schedule of Events for Patients Randomized to No Treatment in 
the Pivotal Study
Month -1 Month 0 Months 1 to 12Month 
13Follow -up
Weeks -4 
to -1
Screening
Day -28 to 
-1 Week 0
Randomization , Weeks 2
and3Weeks 4, 8, 12, 16, 
20, 24, 28, 32, 36, 
40, 44, 48 (± 7 days )Week 
52
End of 
Study 
(EOS)
(± 7 
days )7 (±2) 
Days Post 
EOS Weeks 
4, 16, 
28 40Weeks 8, 
12, 20. 24, 
32, 3 6, 44, 
48
AssessmentDay -28to 
Day -1Day 0No 
assessmentsTelephone Telephone
Informed Consenta●
Revie w of Study Entr y 
Criteria●
Medical History ●
Hunter Syndrome 
Diagnosis and Genotype●
Echocardiogramd●
Physical and Neurological 
Examination● ● ●
Height and Weight ● ● ●
Head Circumference ● ● ●
Hearing Assessment ● ● ●
12-lead ECG ● ● ●
Vital Signs ● ● ●
Clinical Laboratory Tests ● ● ●
General Anesthesia ● ●
Urine GAG ● ● ●
Anti-idursulfase Antibody 
Testing● ● ●
Brain MRI ● ●
ICP measurement ● ●
CSF Sample Collectionc● ●
Randomization ●b
Neurodevelopmental 
Assessment● ●e●e
Health status Questionnaire ● ●
Concomitant Medications, 
Therapies/Interventions, 
Medical/Surgical 
Procedures● ● ● ● ●
Adverse Event s ● ● ● ● ● ●
Abbreviations:  
CSF = cerebrospinal fluid; ECG = electrocardiogram; GAG = glycosaminoglycan; ICP = intracranial pressure; MRI 
= magnetic resonance imaging.
aInformed consent must be obtained from the patient’s parent(s)/legal guardian(s) before begin ning Screening Page 93
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013
Shire Confidential 94Month -1 Month 0 Months 1 to 12Month 
13Follow -up
Weeks -4 
to -1
Screening
Day -28 to 
-1 Week 0
Randomization , Weeks 2
and3Weeks 4, 8, 12, 16, 
20, 24, 28, 32, 36, 
40, 44, 48 (± 7 days )Week 
52
End of 
Study 
(EOS)
(± 7 
days )7 (±2) 
Days Post 
EOS Weeks 
4, 16, 
28 40Weeks 8, 
12, 20. 24, 
32, 3 6, 44, 
48
AssessmentDay -28to 
Day -1Day 0No 
assessmentsTelephone Telephone
procedures.
bPatients will be randomized after completion of Screening assessments.  The day of randomization is Day 0.
cThe CSF sample will be obtained via lumbar puncture and while the patient is under general anesthesia. The
samples will b e used to analyze standard laboratory parameters (chemistries, cell counts), concentrations of 
GAG and idursulfase enzyme , and presence of idursulfase -specific antibodies .
dThis assessment will not need to be performed if an echocardiogram taken within 3 m onths of study start is 
available and deemed satisfactory for evaluation of anesthesia risk. 
eThe neurodevelopmental assessments will be performed at Weeks 16, 28, 40 (±7 days) and at EOS Week 52 (±7 
days).Page 94
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 98Appendix 4 Expected Adverse Device Effects
A list of the adverse effects expected with the SOPH -A-PORT Mini S is provided in this 
appendix.
Procedure -Related Complications
•Components handled improperl y before, during, or after implantation 
•Access port implanted incorrectly
•Catheter positioned improperly
•Injection through septum performed incorrectl y
• Injection of incorrect medication through access port
• Injection outside the access port into pocket or subcutaneous tissue or extravasation
• Pocket seroma, hematoma, erosion, or infection
Intrathecal Access Complications
• Surgical complications such as hemorrhage or hematoma
•Infection of the implant site or catheter track
• Radiculitis or arachnoiditis
•Intrathecal space infection resulting in meningitis or encephalitis
•Bleeding 
• Spinal cord damage or trauma to the spinal cord or nerve roots
•Post-lumbar puncture, cerebrospinal fluid (CSF) leak, leading to headache, or subcutaneous 
CSF collection
•Epidural instead of intrathecal placement of catheter
•Inflammatory  mass resulting in neurological impairment, including paral ysis
•Pain on injection
•Complications of anesthesia
•Pseudomeningocele
System -Related Complications
•Improperl y positioned access port
•Erosion of the skin because of the underly ing access port or the catheter
•Wound dehiscence
•Access port migration, fracture, breakage or occlusion
• Catheter damage, dislodgement, migration, disconnection, kinking or occlusion, fibrosis, or 
hygroma, resulting in tissue damage or a loss of or change in therapy, or other potentially  serious 
adverse health consequences
• Catheter breakage and migration of residual catheter fragments, potentially resulting in 
serious adverse health consequences and the need for surgical removal 
•Loca l immunological or fibrous reaction to the presence of a foreign body  (the device)
• End of device service life or component failure, requiring surgical replacement
•Component failure, resulting in loss of therap y
•Access port inversion (“flipping”), rot ation, or extrusionPage 98
idursulfase -IT
SOPH -A-PORT®Mini S
Clinical Trial Protocol :HGT -HIT-094 04April 2013 
Shire Confidential 99• Access port or catheter rejection 
• Fibrin sheath formation around catheter tipPage 99